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Adult hematopoiesis normally occurs in bone marrow, where hematopoietic stem cells 
(HSC) reside within a specialized microenvironment.  At steady state, hematopoiesis 
state is regulated such that immature hematopoietic stem and progenitor cells (HSPC) are 
restricted to the bone marrow and are rarely observed in peripheral blood.   Under certain 
circumstances, however, this regulation is loosened and significant numbers of HSPC are 
released to the circulation, a process termed “mobilization.”  Mobilization can be induced 
pharmacologically by a wide range of agents.  Of these, the best characterized and most 
widely used mobilizing agent is Granulocyte-colony stimulating factor (G-CSF).   G-CSF 
is widely used clinically and several molecular mechanisms have been 
implicated as mediating its mobilizing action.  However, many questions remain 
as to the relationship between these various pathways.  This work begins by 
focusing on one mobilization pathway, the disruption by G-CSF of signaling 
between CXCL12, a chemokine expressed in the HSC microenvironment, and its 
receptor CXCR4, broadly expressed on hematopoietic cells.  By examining mice 
 xi
genetically deficient in CXCR4, we show that this mechanism is not only the 
predominant pathway by which G-CSF induces mobilization, but also a common 
pathway utilized during treatment with other hematopoietic cytokines.  Next, 
while investigating the mechanism by which G-CSF disrupts CXCL12/CXCR4 
signaling, we unexpectedly uncovered a role for osteoblasts in regulating 
cytokine-induced mobilization.  By isolating and sorting different fractions of 
bone marrow stromal cells we demonstrate that osteoblasts represent a major 
source of CXCL12 in the bone marrow.  In addition, both the number and 
function of mature osteoblasts declines sharply during cytokine treatment.  
Subsequent analysis demonstrated that G-CSF both increases the rate of 
osteoblast apoptosis and blocks osteoblast development.  Finally, experiments 
with G-CSF receptor null chimeras demonstrate that this effect on osteoblasts is 
not direct but is mediated by the hematopoietic compartment.  While the 
regulation of hematopoiesis by osteoblasts has been well described, the 
reciprocal regulation of osteoblasts by bone marrow hematopoietic cells has not 
been widely appreciated.  Further work will be required to determine if this 
regulation occurs not only during the specialized setting of cytokine-induced 
mobilization but during steady state hematopoiesis in general.   
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CHAPTER 1 
 
 
 
 
 
 
INTRODUCTION 
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1.1  Introduction 
     Adult hematopoiesis normally occurs in bone marrow, where hematopoietic stem cells 
(HSC) reside.  This small pool of slow-cycling cells can differentiate into highly 
proliferating committed progenitors of any hematopoietic lineage according to the needs 
of the host.  As these progenitors differentiate into mature hematopoietic cells, they are 
released into the circulation to meet the host’s need for oxygen transport, hemostasis, and 
innate and adaptive immunity.  The hierarchical organization of hematopoiesis serves to 
protect the genomic integrity of the stem cell pool while retaining a proliferative potential 
capable of releasing billions of mature hematopoietic cells into circulation each day.  Not 
surprisingly, then, the localization of HSC within their specialized bone marrow 
microenvironment and the subsequent release of their mature progeny into circulation are 
ordinarily tightly regulated.   
     During periods of stress or injury, however, this strict regulation is loosened, and HSC 
and other primitive hematopoietic progenitors—collectively termed “HPSC”—are  
released from the bone marrow, a process termed “mobilization”.  Conversely, HSC 
delivered intravenously after myoablative conditioning home from the circulation back to 
the bone marrow where they reconstitute recipient hematopoiesis.        
     The discovery in the 1990s that pharmacologic doses of hematopoietic cytokines 
mobilize HSC to the peripheral blood without harming the subject spurred research into 
the clinical feasibility of using mobilized peripheral blood HSC in stem cell transplants. 
1,2
  Mutiple clinical trials showed cytokine-mobilized peripheral blood stem cells to be an 
effective and cost-efficient source of cells for stem cell transplant.3-6  Currently, the  
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majority of therapeutic stem cell transplants worldwide utilize mobilized peripheral blood 
HSC.7,8   
     Despite the wide clinical use of mobilized HSC, much about the mechanisms 
underlying HSPC mobilization remains unclear.  The purpose of this work is to elucidate 
mechanisms by which HSPC are retained in the supportive bone marrow environment at 
steady state and are induced to migrate to the circulation during mobilization.  It is hoped 
that a more precise understanding of these pathways will lead not only to improved 
protocols for HSC mobilization and collection in the transplant setting, but also to new 
insights into the manner in which HSPC are maintained in the bone marrow.   
 
1.2  Hematopoietic stem cells reside within specialized “niches” in the bone marrow. 
     In the strictest sense of the term, a stem cell niche is a specialized microenvironment 
comprised of supporting cells and extracellular matrix where stem cells reside and 
receive signals necessary for their maintenance as stem cells.  In Drosophila ovarioles, 
for example, a germline stem cell niche is provided by somatic cap cells which provide 
signals necessary to maintain the critical balance between germ stem cell self renewal 
and differentiation.9 
     Although the existence of a niche for HSC was first proposed by Schofield in 1978 10, 
its anatomical location has remained unknown until relatively recently.  Early studies 
revealed that primitive CFU-C and CFU-S increase in frequency closer to the endosteal 
surface in long bones.11,12  Similarly, Nilsson et al. showed that sorted bone marrow 
populations enriched for stem cell activity (Rho123 low, lineage negative) preferentially 
homed to endosteal regions.13  These observations raised the possibility that endosteum-
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lining osteoblasts or osteoblast-lineage cells contribute to the stem cell niche.  In vitro, 
osteoblasts abundantly express hematopoietic cytokines G-CSF, GM-CSF, and IL-6.  
Cultured osteoblasts support the maintenance of primitive hematopoietic cells as 
determined by CFU-C and LTC-IC assays.14,15  Recent evidence has suggested that 
osteoblasts play a key role in supporting the stem cell niche in vivo, as well.  Calvi et al 
reported that transgenic expression of a constitutively active form of the parathyroid 
hormone receptor (caPRP) under control of a 2.3kb fragment from the col1a1 locus 
significantly expanded the osteoblast compartment as measured by standard 
histomorphometric techniques.  This increase in osteoblast number was associated with a 
roughtly 2-fold increase in number of LTC-IC and in donor chimerism in a competitive 
repopulation assay, suggesting an increase in HSC number or function.16  In a similar 
system, Zhang et al. expanded the osteoblast compartment by deleting the bone 
morphogenic protein receptor gene bmpr1a in non-hematopoietic cells.  Similar to the 
results in Calvi et al., the increase in osteoblast number and trabecular bone was 
associated with a 2.2-fold increase in number of HSC as determined by limiting dilution 
assay.17    
     In the converse experiment, Visnjic et al. generated a transgenic mouse expressing the 
thymidine kinase suicide gene under control of the col1a1 2.3kb promoter.  Four week 
treatment with gancyclovir resulted in a striking loss of mature osteoblasts and trabecular 
bone.  Hematopoiesis in bone marrow was severely compromised, with a 5-10-fold 
decrease in cellularity, a 3-10-fold decrease in primitive c-Kit positive, Sca-1 positive, 
lineage negative (KSL) cells, and extensive extramedullary hematopoiesis.18  
Collectively, these studies suggest that the size of the HSC pool relates directly to the 
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osteoblast compartment, consistent with the possibility that osteoblasts play an important 
role in the HSC niche.    
     Much study has been given recently to understanding the molecular signals by which 
osteoblasts might regulate HSC.  Osteoblasts express the adhesion molecule VCAM-1 
and the chemokine Stromal-derived factor 1 (SDF-1/CXCL12), which play a role in HSC 
retention in the marrow (see below).19-21  Calvi et al. observed enhanced osteoblast 
expression of Notch ligand Jagged-1 in their caPRP transgenic mice, and inhibitors of 
Notch signaling abrogate the enhanced LTC-IC numbers in their model, suggesting that 
Notch signaling contributes to HSC support in the osteoblastic niche.16   In a different 
study, quiescence in HSC was identified with Tie-2 expression, and Tie-2 positive HSC 
were identified along endosteal surfaces.  Tie-2 ligand angiopoietin 1 (Ang-1), which is 
expressed by osteoblasts, promoted maintenance of HSC quiescence and preserved long-
term repopulating ability in ex vivo cultured HSC.22  Osteoblasts also express several 
wingless (Wnt) family members, which have been implicated as important paracrine 
factors in maintaining the HSC pool.23,24    
     Besides factors expressed by osteoblasts, certain properties of the endosteal niche may 
contribute to HSC maintenance.  Oxygen tension along the endosteal surface is lower 
than in the bone marrow proper, which might serve to lower the risk of HSC sustaining 
oxidative damage,25 and HSC cultured in low oxygen conditions retain their repopulating 
activity better than HSC cultured in normoxia.26  Similarly, local calcium ion 
concentrations along the endosteal surface are much higher than elsewhere in the bone 
marrow.27  Lack of CaR, a calcium-sensing G-protein-coupled receptor expressed on 
HSC, leads to loss of HSC in the bone marrow, suggesting that the local calcium ion 
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concentration along the endosteal surface might contribute to HSC support.28  Taken 
together, these findings suggest an important role for osteoblast-lineage cells in 
supporting HSC along bone marrow endosteal surfaces.   
     Despite the above-mentioned findings, the precise characterization of the HSC-
supporting osteoblast population remains unclear.  Zhang et al. show that slow-cycling, 
hematopoietic cells found along endosteal surfaces were localized near N-cadherin 
positive, spindle shaped bone lining cells (SNO cells), raising the possibility that this 
subset of osteoblastic cells defines the stem cell niche.  Likewise, it is possible that other 
stromal components contribute to the stem cell niche.  For example, Sugiyama et al. have 
identified a population of reticular stromal cells that localize near endosteal surfaces as 
well as elsewhere in the marrow.  These cells, termed “CAR” cells (CXCL12-abundant 
reticular cells), express high levels of SDF-1, raising the possibility that they contribute 
to HSC maintenance in the bone marrow.29     
     Besides an endosteal stem cell niche, some evidence suggests that specialized bone 
marrow endothelium provides an additional niche for HSC.  Recent advances in 
technology have allowed for identification of cell populations highly enriched for HSC.  
Kiel et al. showed that roughly half of CD150 positive, CD48 negative cells (SLAM 
cells) are true stem cells.30  Surprisingly, immunofluorescent imaging localized only a 
small fraction of this population to the endosteal surface.  The majority of SLAM cells 
were shown in the bone marrow adjacent to bone marrow sinusoids, suggesting that bone 
marrow endothelial cells may constitute a second HSC niche.  In contrast, Sugiyama et 
al. showed SLAM cells localized to endothelial-associated CAR cells rather than to 
endothelium itself.29   Despite these findings, there is currently no data linking 
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endothelial or CAR cells to HSC function.  However, Sacchetti et al. showed that human 
reticular adventitial cells located adjacent to endothelium and expressing CD146 were 
necessary and sufficient to form ectopic bone when xenotransplanted into 
immunocompromise mice.  This ectopic bone was colonized by hematopoietic cells, 
suggesting that these endothelium-associated CD146 positive cells may functionally 
support stem cells in vivo.31  
     In summary, the support of resident non-hematopoietic cells is critical for the 
maintenance of HSC in the bone marrow.  In particular, osteoblasts fulfill the criteria for 
stem cell niche-defining cells in that their expansion results in increased HSC numbers 
and their ablation causes loss of hematopoiesis in the bone marrow.   The observation that 
HSC localize to areas other then endosteal surfaces suggests, however, that HSC may 
reside in more than one niche and may indeed traffic between niches.  Interestingly, 
despite their need to reside in a niche for long-term functioning, under certain 
circumstances HSC are observed to leave their bone marrow niche and are released to the 
circulation. 
 
1.3  Mobilization of HSC from the bone marrow niche. 
     As described above, the release of hematopoietic cells from the bone marrow is tightly 
regulated to ensure that immature cells are retained in the bone marrow.  Nevertheless, it 
has long been appreciated that low numbers of hematopoietic stem and progenitor cells 
(HSPC) can, in fact, be observed in the circulation.32,33    
     Whether these circulating HSPC serve a teleological function is unknown.  
Experiments in parabiotically joined mice demonstrate that circulating HSPC are able to 
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colonize distant sites, leading to speculation that circulating progenitors aid recovery 
from injury or infection.34  Recent evidence for this hypothesis was provided by 
Massberg, et al. who showed that circulating HSPC can proliferate and differentiate into 
dendritic cells within peripheral organs in response to stimulation by Toll-like receptor 
agonists.35  At baseline, these circulating HSPC are  extremely low in number, estimated 
100-400 per mouse.36  However, a wide range of physiologic and pharmacologic 
stimuli—including bone marrow stress, hypoxia, infection, and cytotoxic drugs—can 
significantly increase the number of circulating HSPC, lending further credibility to the 
hypothesis that circulating HSPC aid recovery from injury (reviewed in 37).   
     Mobilization can be induced by a wide variety of pharmacologic agents, including 
chemokines, cytokines, and cytotoxic drugs (see table 1).  Besides these three broad 
classes, however, a surprisingly diverse list of mobilizing agents is accumulating.  These 
include such disparate molecules as lipopolysachharide (LPS) and fucoidan, a sulfated 
polysaccharide isolated from seaweed.38-40  As the molecular underpinnings of 
mobilization are elucidated, a second generation of mobilizing agents are being designed 
to activate specific mobilizing pathways.  For example, AMD3100, a small molecule 
inhibitor of CXCR4, has been studied extensively in animal models and has undergone 
phase I clinical trials in both autologous and allogeneic settings.41-43   
     Mobilizing agents exhibit considerable diversity both in their presumed molecular 
targets as well as their kinetics, which range from 15-30 minutes to peak mobilization in 
the case of chemokines to greater than 5 days in the case of hematopoietic cytokines.  
Given this diversity, it is likely that multiple mechanisms exist for the mobilization of 
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hematopoietic progenitors.  At the same time, the possibility remains that at least certain 
subsets of mobilizing agents may share common pathways.   
  
Table 1.1.  
Parial list of 
mobilizing 
agents 
[adapted 
from 
Thomas et 
al. Current 
opinion in 
hematology 
(2002)]  
 
    Although both G-CSF and GM-CSF are currently approved for clinical use, the best 
studied and most widely used mobilizing agent is G-CSF.  As will be discussed below, 
three general mechanisms have been implicated in mediating G-CSF-induced 
mobilization: 1) induction of bone marrow proteases, which are believed to cleave ECM 
and degrade key signaling molecules; 2) downregulation of adhesion molecules that 
maintain HSPC in the bone marrow at steady state; and 3) disruption of SDF-1/CXCR4 
signaling, which is thought to signal to retain HSPC in the bone marrow.   
 
1.4  Induction of proteases is a common motif in HSPC mobilization. 
     Treatment with G-CSF dramatically increases the myeloid content of the bone marrow 
along with a corresponding increase in the activity of neutrophil-derived serine proteases 
neutrophil elastase (NE) and cathepsin G (CG) as well as metalloproteinase 9 (MMP9).62  
Additionally, bone marrow expression of serpin family protease inhibitors decreases, 
resulting in the induction of a proteolytic bone marrow environment.63  Proteolytic 
cleavage of ECM may facilitate HSPC migration from the extramedullary space to the 
Mobilizing Agent Mobilization Time to peak response Reference 
G-CSF 20-100-fold increase 7-14 days 44,45 
GM-CSF 45-fold increase 7 days 46,47 
Flt-3 ligand 500-fold increase 7 days 48-50 
Stem Cell Factor 20-fold increase 7-10 days 47,51 
VEGF 10-fold increase 5 days 52 
Cyclophosphamide 62-fold increase 8 days 53,54 
MIP1α 5-10-fold increase 15-30 minutes 55,56 
Groβ 5-10-fold increase 15-30 minutes 57 
Fucoidan 7-30-fold increase 30min-2 hr 38 
LPS 8-fold 5 days 39,40,58 
Pertussis Toxin 10-20-fold 3-4 days 59 
AMD3100 5-fold 1 hr 43 
Intense Exercise 4-fold n.a. 60,61 
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circulation.  Also, enhanced protease activity might promote cleavage of adhesion 
molecules that tether HSPC to their stromal environment and degrade critical signaling 
molecules to facilitate HSPC mobilization.  In support of this model, bone marrow 
extracts from treated mice have been shown to cleave the VCAM-1 adhesion molecule as 
well as chemokine SDF-1 and its receptor CXCR4.64-66  Furthermore, MMP-9 can cleave 
in vitro the tyrosine-kinase receptor c-Kit which is expressed on HSPC.67  Treating mice 
with inhibitors to NE or both NE and CG inhibited G-CSF-induced HSPC mobilization, 
and mobilization was blunted 40-50% in mice treated with anti-MMP9 neutralizing 
antibody.66,68   These findings, however, contrast with other data showing that G-CSF-
induced mobilization is unaffected in NE knockout mice, NE x CG knockout mice, 
MMP-9 knockout mice, and DPP1 knockout mice which are unable to activate neutrophil 
serine proteases in general.69  Possible explanations for this discrepancy include the 
developmental adaptation of mice deficient from birth in certain proteases or the 
difference in strains used in these studies.  Nevertheless, there currently exists no genetic 
evidence that neutrophil proteases play a role in G-CSF-induced mobilization. 
     Similar to G-CSF, there is evidence that protease upregulation plays a role in 
chemokine-induced mobilization.  Treatment with CXCR2 ligands Groβ and IL8 increase 
plasma and bone marrow levels of MMP9, and treatment with neutralizing antibody 
against MMP9 or the broad-spectrum protease inhibitor serpin 1a/α1 antitrypsin blocked 
IL8-induced mobilization.68,70,71  Curiously, while Groβ treatment mobilizes poorly in 
MMP9 deficient mice, IL8 mobilization occurs normally.68,71   
     The implication of neutrophil proteases in chemokine-induced mobilization, along 
with the observation that neutrophils are activated both by chemokines and G-CSF, has 
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led to the hypothesis that neutrophils play a key role in mobilization.72,73  Indeed, 
peripheral neutropenias induced either by clearance with an antibody against Gr-1 or 
genetically in G-CSF receptor deficient mice prevents mobilization with IL-8.71,74  The 
role of peripheral blood neutrophils is less clear in G-CSF-induced mobilization, 
however, as mixed G-CSFR knockout and wildtype bone marrow chimeras mobilize 
poorly with G-CSF despite having a normal complement of wild type neutrophils in 
circulation. (Link DC, unpublished data)     
 
1.5 Adhesion molecules mediate HSPC retention in the bone marrow 
microenvironment. 
 
The trafficking of HSPC from their local bone marrow microenvironment and release 
into circulation is thought to involve downregulation of adhesion molecules that normally 
govern interaction between HSPC and their local stromal and ECM elements.  
Hematopoietic cells widely express β1 and β2 integrins.  β1 integrins VLA-4 and VLA-5 
(α4β1 and α5β1) are expressed on bone marrow HSPC and their ligands are expressed on 
stromal cells and bone marrow ECM.   VLA-4 expression and activity are high in bone 
marrow HSPC and decrease with differentiation.  Given that HSPC are preferentially 
retained in the bone marrow, this observation raises the possibility that VLA-4 in 
particular may play a role in the release of mature hematopoietic cells during 
mobilization.75,76  Indeed, treatment with anti-VLA5 antibody results in a modest HSPC 
mobilization in mice, and anti-VLA-4 antibody causes robust HSPC mobilization in mice 
and rhesus monkeys.77,78  Similarly, mice with an induced deletion of the gene encoding 
α4 integrin have an elevated level of peripheral blood HSPC.79  Finally, neutralizing 
antibody against vascular cell adhesion molecule 1 (VCAM-1), an immunoglobulin 
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superfamily member and VLA-4 ligand present on stromal cells,  mobilizes HSPC to a 
similar extent as VLA-4 neutralization.  Together, these findings suggest that VLA-
4/VCAM-1 specifically mediate a HSPC/stromal cell interaction that retains HSPC in the 
bone marrow.  80   
    In contrast to the β1 integrins, whose neutralization leads to HSPC mobilization, β2 
integrin neutralization does not result in elevated HSPC numbers in peripheral blood.  
However, β2 integrin neutralization, either with neutralizing antibody or by genetic 
deletion, results in enhanced mobilization with VLA-4 neutralization, suggesting that β2 
integrins may co-operate with β1 integrins in maintaining HSPC in the bone marrow but 
do not play a necessary role.78 
     Besides integrins, HSPC adhesion in the bone marrow microenvironment involves 
CD44, the receptor for hyaluronan, a gycosaminoglycan component of the ECM.   
Neutralizing antibodies against CD44 disrupt progenitor adhesion to fibronectin in vitro 
and cause a modest mobilization of HSPC in vivo.81,82  On the other hand, CD44 null 
mice treated with G-CSF have attenuated rather than enhanced mobilization, suggesting 
that CD44 plays a more complex role than simply mediating HSPC retention to the bone 
marrow.82   
 
1.6  SDF-1/CXCR4 signaling maintains HSPC in their bone marrow niche.  
    In addition to the role played by proteases and adhesion molecules in mediating HSPC 
mobilization, signaling between chemokine SDF-1 and its receptor CXCR4 has emerged 
in recent years as a third major mechanism regulating HSPC trafficking.  SDF-1 
(CXCL12), a chemokine of the C-X-C family, was initially discovered in a screen of 
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stromal cell line conditioned media as a chemoattractant for human CD34 positive 
progenitor cells.83  Its primary receptor, CXCR4, is a G-protein-coupled seven 
transmembrane chemokine receptor present on bone marrow hematopoietic cells as well 
as neuronal, endothelial, and epithelial cells.84  Several lines of evidence suggest a model 
wherein SDF-1, expressed by bone marrow stromal cells, signals to hematopoietic cells 
through CXCR4 to cause their retention in the bone marrow.   
     First, genetic ablation of CXCR4 signaling impairs retention of HSPC in the bone 
marrow.  Mice deficient in either SDF-1 or CXCR4 die in late gestation with several 
developmental defects, including a failure of hematopoietic cells to colonize the bone 
marrow.  SDF-1 knockout embryos have a high number of circulating hematopoietic 
stem cells, however, suggesting either a failure to home or a failure to be retained in the 
marrow. 85,86  CXCR4 null fetal liver cells do not engraft irradiated recipients efficiently 
despite homing normally to the bone marrow, again suggesting a defect in retention.87  
Resulting CXCR4 null chimeras have a high number of circulating HSPC.88  Conversely, 
hypermorphic mutations in the CXCR4 gene that lead to enhanced signaling result in a 
human disease characterized by a failure of myeloid cells to be released normally from 
the bone marrow.89,90 
     Next, antagonism of CXCR4 signaling with AMD3100, a small molecule inhibitor, 
leads to rapid release of HSPC to the peripheral blood.91  Continuous administration of 
AMD3100 leads to sustained and robust HSPC mobilization.92  Similarly, administration 
of proteoglycans fucoidan and dextran sulfate both lead to mobilization with an 
concurrent reduction of bone marrow SDF-1.93 
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     Finally, as will be described later, mobilization of HSPC during G-CSF treatment is 
associated with decrease of bone marrow SDF-1 protein and mRNA that mirrors the 
kinetics of mobilization.21,66  At the same time, CXCR4 surface expression and signaling 
decrease on mobilized progenitor cells compared to bone marrow HSPC, suggesting that 
G-CSF-induced loss of CXCR4 on a subset of HSPC cells may synergize with loss of 
bone marrow SDF-1 during mobilization.64    
     The downstream cellular mechanisms by which CXCR4 signaling promotes retention 
in the bone marrow have not been fully elucidated.  SDF-1 binding CXCR4 in human 
CD34 positive cells activates multiple signaling pathways including phosphatidylinositol 
3-kinase (PI3K), protein kinase C (PKC), and mitogen-activated protein kinases ERK-1 
and -2. These events lead to tyrosine phosphorylation of focal adhesion components 
related adhesion focal tyrosine kinase (RAFTK) and the cytoskeletal protein paxillin.  
Subsequent cytoskeleton reorganization and cell migration can be blocked with small 
molecule inhibitors to PI3K and PKC.94,95  However, it is not fully clear whether 
hematopoietic progenitors remain in the bone marrow simply via chemotactic signaling 
toward a gradient of SDF-1 produced by bone marrow stromal cells or whether other 
cellular processes are involved.  Incubation of HSPC with SDF-1 increased VLA-4 
affinity for its ligands and enhanced endothelial transmigration in a VLA-4 and VLA-5-
dependent fashion in vitro, suggesting that SDF-1 signaling may promote HSPC retention 
in the niche through regulation of adhesion molecules as well as providing a chemotactic 
signal.96,97 
      In sum, these data suggest that the SDF-1/CXCR4 interaction is crucial for retention 
of hematopoietic cells in the bone marrow and that disruption of that interaction leads to 
 15 
mobilization.  How treatment with G-CSF and other mobilizing agents disrupt this 
interaction, however, is a matter of ongoing investigation.      
 
1.7  Disruption of SDF-1/CXCR4 signaling during mobilization.   
     During treatment with G-CSF, SDF-1 protein decreases in the bone marrow.  
However, some controversy exists as to how this occurs.  One hypothesis is that SDF-1 
protein is degraded by bone marrow proteases.  Christophersen et al. showed that CD26, 
a cell-membrane-associated dipeptidyl peptidase, inactivates SDF-1 by cleaving its amino 
terminal two residues.98  Indeed, mice deficient in CD26 have a less severe drop in bone 
marrow SDF-1 and less robust mobilization in response to G-CSF.99  Expression of 
CD26, however, does not change with G-CSF treatment, so while this mechanism may 
function basally to clear SDF-1 from the marrow, it cannot account for the decrease 
during G-CSF treatment.  
     In contrast to CD26, bone marrow levels of neutrophil-derived proteases NE, CG, and 
MMP9 increase during G-CSF treatment.  Bone marrow extracts from G-CSF-treated 
mice cleave SDF-1 in vitro, which has led to the hypothesis that these proteases mediate 
mobilization in part by degrading SDF-1.64,66  However, as noted above, mice deficient in 
neutrophil serine proteases as well as mice treated with broad spectrum metalloproteinase 
inhibitors mobilized normally,69 indicating that these specific proteases are not required 
for SDF-1 degradation.  Nevertheless, the great number and overlapping functions of 
proteases makes it difficult to rule out a role for proteolytic cleavage of SDF-1 based on 
knockout studies.   
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     Alternatively, it is possible that G-CSF treatment leads to a fall in bone marrow SDF-1 
by decreasing its expression.  As discussed in Chapter 2 of this thesis, G-CSF treatment 
leads to a fall in total bone marrow SDF-1 mRNA with similar kinetics to the fall in SDF-
1 protein, suggesting that this may be the primary mechanism by which G-CSF targets 
bone marrow SDF-1.21,100  Finally, outside the context of hematopoietic mobilization, 
other studies have shown SDF-1 levels to be transcriptionally regulated.101-103 
     Notably, while downregulation of SDF-1 likely plays an important role in G-CSF-
induced mobilization, it is unclear to what extent disruption of SDF-1/CXCR4 signaling 
plays a role in mobilization induced by other mobilizing agents.  No data has been 
published examining the disruption SDF-1/CXCR4 signaling in bone marrow of mice 
mobilized with other cytokines or with cytotoxic agents.  The kinetics and extent of 
mobilization induced by these agents, however, are similar to that of G-CSF and are 
compatible with a role for SDF-1 downregulation.  In contrast, chemokine induced 
mobilization, which peaks within half an hour of chemokine administration, does not 
likely involve a transcriptional downregulation of SDF-1, and indeed, mobilization 
induced by the chemokine Groβ does not result in loss of bone marrow SDF-1.68  
Nevertheless, the possibility remains that attenuated CXCR4 signaling may contribute to 
mobilization induced by chemokine administration.  One novel pathway by which this 
may occur is heterologous desensitization, a phenomenon wherein CXCR4 signaling may 
be blunted by activation of co-expressed cytokine receptors.  A recent study showed that 
treatment of neutrophils with the CXC chemokine KC led to heterologous desensitization 
of CXCR4.104 This effect, however, is not observed with all chemokine receptors, 
suggesting that downregulation of SDF-1/CXCR4 signaling is not the only mechanism 
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leading to neutrophil release.105  Currently, however, there is no evidence for 
heterologous desensitization of CXCR4 signaling playing a role in HSPC mobilization.   
     To summarize, G-CSF-induced mobilization is associated with a loss of SDF-1 
protein and mRNA in the bone marrow.  While proteolytic degradation may play a role in  
SDF-1 degradation, the loss of SDF-1 mRNA suggests that G-CSF treatment targets 
SDF-1 transcription in the stromal components of the stem cell niche during HSPC 
mobilization.  To understand how SDF-1 mRNA is downregulated during G-CSF 
treatment, it is necessary to identify which bone marrow cell types produce SDF-1.    
 
1.8  SDF-1-producing cells in the bone marrow.  
     The drop in SDF-1 mRNA in the bone marrow suggests that G-CSF targets one or 
more SDF-1-producing cell populations in the bone marrow, leading to decreased SDF-1 
mRNA.  Some controversy exists regarding the exact identity of the populations that 
express SDF-1, and it has not yet been shown if any of these downregulate SDF-1 
expression during G-CSF treatment.  In vitro, the literature reports SDF-1 expression in 
immortalized stromal cell lines, primary endothelial cells, primary osteoblasts, and cell 
lines derived from those cell types.20,86,106,107  Demonstrating SDF-1 expression in vivo, 
however, has proven more difficult.  Ponomaryov et al. showed human SDF-1 expression 
in bone-lining osteoblasts, endothelial cells, and scattered, spindle-shaped stromal cells.20  
On the other hand, Ara et al., using a transgenic mouse in which the GFP cDNA was 
inserted into the SDF-1 locus, showed no colocalization of mouse SDF-1 with endothelial 
marker PECAM-1.108  Using this system, little or no SDF-1 expression was detected co-
localized with osteocalcin, a specific osteoblast marker, although SDF-1 expression did 
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co-localize with a subset of VCAM-1 positive cells with reticular morphology termed 
“CAR” cells that could be found in close proximity to endothelial cells (see above).29,109  
These conflicting results are difficult to interpret, as it is difficult to tell whether replacing 
exon 2 of the CXCL12 locus with a GFP expression cassette has resulted in disregulated 
signaling.  Further, the lack of co-expression with osteocalcin does not necessarily rule 
out SDF-1 expression by osteoblasts, as osteocalcin is a late osteoblast marker expressed 
only in a fraction of morphologically identifiable, functional osteoblasts.110  
     In sum, most studies to date report SDF-1 expression across a spectrum of non-
hematopoietic cells in the bone marrow.  Even so, further work is needed to resolve 
whether these populations include endothelial cells or osteoblasts.   
 
1.9 Summary 
     Under normal circumstances, HSC reside in bone marrow stem cell niches which 
provide critical support at a molecular level to maintain their function as stem cells.  
Evidence from mouse models with enhanced osteoblastogenesis suggests that osteoblasts 
in particular compose a necessary part of the HSC niche.  HSPC can be mobilized from 
the bone marrow in response to treatment with certain mobilizing agents, the best 
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characterized and most widely used of which is G-CSF.   Several mechanisms likely play 
a role in G-CSF-induced mobilization, including induction of bone marrow neutrophil-
derived proteases, downregulation of critical adhesion molecules, and disruption of SDF-
1/CXCR4 signaling due in part to loss of bone marrow SDF-1 (see figure 1).   
     However, certain questions remain.  First, what is the relationship between these 
several mechanisms in G-CSF-induced mobilization?  Do they operate independently of 
each other or do they work in tandem?  Next, to what extent do other mobilizing agents 
take advantage of these pathways to induce mobilization?  Of note, the fall in bone 
marrow SDF-1 takes place over days during G-CSF treatment, raising the possibility that 
other cytokine family members—which also mobilize over a period of days—induce 
mobilization in part by dropping bone marrow SDF-1.  Finally, what accounts for the loss 
of bone marrow SDF-1 during G-CSF treatment?  What cell types make SDF-1 normally 
in the bone marrow, and which of these are targeted during G-CSF treatment? 
     In Chapter 2 different subsets of bone marrow stromal cells will be tested for SDF-1 
production and a mechanism will be proposed by which G-CSF treatment causes loss of 
Bone 
HSC 
osteoblasts 
Bone 
Marrow 
CAR cell 
↑proteases         
↓adhesion molecules 
↓SDF-1/CXCR4 
G-CSF 
Figure 1.1  G-CSF disrupts 
the stem cell niche.  
Hematopoietic stem cells 
(HSC) are localized at steady 
state along endosteal surfaces.  
Their maintenance depends on 
the presence of osteoblasts and 
potentially other cell types 
(CAR cells=CXCL12-abundant 
reticular cells.)   G-CSF 
treatment leads to upregulation 
of bone marrow proteases, 
downregulation of adhesion 
molecules VCAM-1/VLA-4 
and disrupts SDF-1/CXCR4 
signaling, leading to stem cell 
mobilization 
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bone marrow SDF-1 by targeting osteoblasts. Chapter 3 will extend these findings, 
investigating whether mobilizing cytokines Flt3 ligand (Flt3L) and stem cell factor (SCF) 
work in part by disrupting SDF-1/CXCR4 signaling and whether targeting of osteoblasts 
represents a common motif in cytokine-induced mobilization.  Further, the relative 
importance of disrupted SDF-1/CXCR4 signaling vis-à-vis other pathways is tested by 
examining G-CSF induced mobilization in the genetic absence of CXCR4.  Finally, 
Chapter 4 examines the effect of G-CSF on osteoblasts in more detail, focusing on G-
CSF effects on osteoblast differentiation and apoptosis.  Chapter 5 synthesizes these 
findings concerning cytokine effects on the stem cell niche with unpublished data 
concerning HSC function after G-CSF treatment and summarizes future directions.   
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CHAPTER 2 
 
 
 
 
 
 
G-CSF POTENTLY INHIBITS OSTEOBLAST ACTIVITY AND 
CXCL12 mRNA EXPRESSION IN THE BONE MARROW 
 
 
 
 
 
 
 
 
The experiments presented in Figures 2.1-2.4 are the work of Dr. Craig Semerad, a 
former post-doctoral fellow in the lab. 
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2.1  ABSTRACT 
There is accumulating evidence that interaction of stromal cell derived factor-1 (SDF-
1/CXCL12) with its cognate receptor, CXCR4, generates signals that regulate 
hematopoietic progenitor cell (HPC) trafficking in the bone marrow.  During 
granulocyte-colony stimulating factor (G-CSF)-induced HPC mobilization, CXCL12 
protein expression in the bone marrow decreases.  Herein, we show that in a series of 
transgenic mice carrying targeted mutations of their G-CSF receptor and displaying 
markedly different G-CSF induced HPC mobilization responses, the decrease in bone 
marrow CXCL12 protein expression closely correlates with the degree of HPC 
mobilization.  G-CSF treatment induced a decrease in bone marrow CXCL12 mRNA that 
closely mirrored the fall in CXCL12 protein.  Cell sorting experiments showed that 
osteoblasts and to a lesser degree endothelial cells are the major sources of CXCL12 
production in the bone marrow.  Interestingly, osteoblast activity, as measured by 
histomorphometry and osteocalcin expression, is strongly downregulated during G-CSF 
treatment.  However, the G-CSF receptor is not expressed on osteoblasts, accordingly G-
CSF had no direct effect on osteoblast function.  Collectively, these data suggest a model 
in which G-CSF, through an indirect mechanism, potently inhibits osteoblast activity 
resulting in decreased CXCL12 expression in the bone marrow.  The consequent 
attenuation of CXCR4 signaling ultimately leads to HPC mobilization. 
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2.2  INTRODUCTION 
The majority of hematopoietic progenitor cells (HPC) reside in the bone marrow 
surrounded by a complex, highly organized microenvironment.  Under normal 
conditions, a small number of HPC are released into the peripheral blood.  Agents with 
distinct cellular targets and biological activities can induce the mobilization of HPC into 
blood, including hematopoietic growth factors, chemotherapeutic agents, and 
chemokines.1,2  Recently, mobilized peripheral blood HPC have become the principal 
cellular source for reconstitution of the hematopoietic system following myeloablative 
therapy.  Currently, granulocyte-colony stimulating factor (G-CSF) is the most widely 
used agent to induce HPC mobilization due to its potency, predictability and safety.3  
However, the mechanisms responsible for G-CSF-induced HPC mobilization have not 
been defined. 
 We previously showed that G-CSF receptor (G-CSFR) expression on HPC is not 
required for their mobilization by G-CSF, suggesting that G-CSF induces HPC 
mobilization indirectly through the generation of trans-acting signals.4  The nature of the 
trans-acting signal(s) that mediate G-CSF-induced HPC mobilization is unknown; 
however, there is accumulating evidence suggesting that interaction of CXCL12 
(stromal-derived factor-1) with its cognate receptor, CXCR4, may play an important role 
in regulating G-CSF-induced HPC mobilization.  CXCL12 is a CXC chemokine 
constitutively produced in the bone marrow by stromal cells.5  Studies of CXCL12 or 
CXCR4 deficient mice have established that these genes are necessary for the normal 
migration of HPC from the fetal liver to the bone marrow and in the efficient retention of 
myeloid precursors in the adult bone marrow.6,7  Moreover, treatment with AMD-3100, a 
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specific antagonist of CXCR4, induces rapid and robust HPC mobilization in both 
humans and mice. 8,9 Finally, we and others showed that CXCL12 protein expression in 
the bone marrow is significantly decreased following G-CSF treatment.10-12.  
Collectively, these data suggest a model in which disruption of CXCL12/CXCR4 
signaling is a key step in G-CSF induced HPC mobilization.   
The mechanism(s) mediating the G-CSF induced decrease in CXCL12 protein 
expression in the bone marrow have not been defined.  Previous reports suggested that 
neutrophil elastase (NE) and cathepsin G (CG) might regulate CXCL12 protein 
expression in the bone marrow through proteolytic cleavage of CXCL12.10,11 However, 
mice genetically lacking NE and CG display normal G-CSF induced HPC mobilization, 
and the expected decrease in bone marrow CXCL12 protein was observed.13  Thus, the 
G-CSF-induced decrease in CXCL12 protein expression in the bone marrow does not 
require these proteases.  It is possible that other proteases can compensate for the loss of 
NE and CG.  Alternatively, non-proteolytic mechanisms may regulate CXCL12 
expression in the bone marrow during G-CSF induced HPC mobilization.   
 In this study, we characterize G-CSF induced HPC mobilization and CXCL12 
expression in the bone marrow in a series of transgenic mice carrying targeted mutations 
of their G-CSFR. We provide further evidence that disruption of CXCL12/CXCR4 
signaling in the bone marrow is a key step in HPC mobilization.  G-CSF regulates 
CXCL12 expression in the bone marrow primarily at the mRNA level.  Evidence is 
provided that G-CSF inhibits osteoblast number and activity through an indirect 
mechanism leading to decreased CXCL12 expression in the bone marrow.   
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2.3  METHODS 
Mice.  GEpoR, d715, and d715F deficient mice were generated, as described 
previously.14-16  GEpoR, d715 and d715F mice were backcrossed 10 generations onto a 
C57BL/6 background. Six to ten week-old mice were used in all studies.  Mice were 
housed in a specific pathogen-free environment.  All experiments were approved by the 
Washington University Animal Studies Committee. 
 
Mobilization protocols.  G-CSF.  Recombinant human G-CSF (Amgen, Thousand Oaks, 
CA) diluted in phosphate-buffered saline (PBS) with 0.1% low endotoxin bovine serum 
albumin (Sigma, St. Louis MO) was administered by daily subcutaneous injection at a 
dose of 250 µg/kg or 100 µg/kg per day for 5 days.  Mice were analyzed 3-4 hours after 
the final G-CSF dose.  AMD3100.  AMD3100, a generous gift from AnorMED Inc. 
(British Columbia, Canada), was reconstituted in sterile PBS and administered as a single 
subcutaneous injection at a dose of 5 mg/kg.  Mice were analyzed 3 hours post-injection 
or at the indicated times. 
 
Peripheral Blood and Bone Marrow Analysis.  Blood was obtained by retroorbital 
venous plexus sampling in polypropylene tubes containing EDTA.  Complete blood 
counts were determined using a Hemavet automated cell counter (CDC Technologies, 
Oxford, CT).  Bone marrow was harvested by flushing with α-modification of eagle’s 
medium (α-MEM) containing 10% fetal calf serum.  Bone marrow extracellular fluid was 
obtained by flushing each femur with 1 ml of ice-cold PBS without serum, and the 
supernatant was harvested after centrifugation at 400 x g for 3 minutes. 
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CXCL12α ELISA.  96-well plates were coated with 100 µl of CXCL12 capture antibody 
(2 µg/ml) diluted in PBS and incubated overnight at room temperature.  After incubation 
for one hour at room temperature with 300 µl of blocking solution [1% bovine serum 
albumin (BSA), 5% sucrose, and .05% NaN3], 100µl of sample was added to each well 
and incubated for 2 hours at room temperature.  After washing, 100 µl of polyclonal 
biotinylated anti-human CXCL12 (250 ng/mL) in ELISA diluent (0.1% BSA, .05% 
Tween 20 in Tris-buffered saline at pH7.3) was added to each well and incubated at room 
temperature for 2 hours.  The reaction was developed by successive incubations with 1 
µg/ml horseradish peroxidase streptavidin, substrate solution, and 50 µl of 2N H2SO4 to 
stop the reaction.  A microplate reader set at 450 nm was used to determine optical 
density with readings at 550 nm subtracted from the results.  Recombinant human 
CXCL12α was used to generate a standard curve.  All ELISA reagents were purchased 
from R&D Systems (Minneapolis, MN). 
 
Colony-forming cell assay.  Blood, bone marrow, and spleen cells were harvested from 
mice using standard techniques and the number of nucleated cells in these tissues 
quantified using a Hemavet automated cell counter.  We plated 10-20 µl blood, 1 x 105 
nucleated spleen cells, or 2.0 x 104 nucleated bone marrow cells in 2.5 ml 
methylcellulose media supplemented with a cocktail of recombinant cytokines 
(MethoCult 3434; Stem Cell Technologies, Vancouver, British Columbia, Canada).  
Cultures were plated in duplicate and placed in a humidified chamber with 6% carbon 
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dioxide (CO2) at 37° C.  Colonies containing at least 50 cells were counted on day 7 of 
culture. 
 
Real-time quantitative RT-PCR.  Femurs were flushed with a total of 2 ml Trizol 
reagent (Invitrogen, Carlsbad, CA) followed by crushing of the remaining bone in Trizol.  
RNA was isolated according to the manufacturer’s instructions and resuspended in 150 µl 
RNase/DNase free water.  Real-time reverse transcriptase-polymerase chain reaction 
(RT-PCR) was performed using the TaqMan One-step RT-PCR Master Mix Reagents Kit 
(Applied Biosystems, Foster City, CA) on a GeneAmp 5700 Sequence Detection System 
(Applied Biosystems).  The reaction mix consisted of 5 µl RNA, 12.5 µl RT-PCR 
reaction mix, 200 nM forward primer, 200 nM reverse primer, 280 nM internal probe, 
and .625 µl Multiscribe reverse transcriptase and RNase inhibitor in a total reaction 
volume of 25 µl.  Reactions were repeated in the absence of reverse transcriptase to 
confirm that DNA contamination was not present.  RNA content was normalized to 
murine β-actin.  PCR conditions were 48°C for 30 minutes and 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.   
CXCL12 forward primer: 5′-GAGCCAACGTCAAGCATCTG–3′;  
CXCL12 reverse primer: 5′-CGGGTCAATGCACACTTGTC–3′;  
CXCL12 dT-FAM/TAMRA probe: 5′-TCCAAACTGTGCCCTTCAGATTGTTGC–3′;  
β-actin forward primer: 5′- ACCAACTGGGACGATATGGAGAAGA–3′;  
β-actin reverse primer: 5′- TACGACCAGAGGCATACAGGGACAA–3′;  
β-actin dT-FAM/TAMRA probe: 5′- AGCCATGTACGTAGCCATCCAGGCTG–3′. 
Osteocalcin forward primer: 5'-TCTCTCTGCTCACTCTGCTGGCC-3' 
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Osteocalcin reverse primer: 5'-TTTGTCAGACTCAGGGCCGC-3' 
Osteocalcin dT-FAM/TAMRA probe: 5'-
TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3' 
 
Cell Sorting.  Bone marrow cells were recovered from the femurs and tibia of mice by 
extensive flushing with 40 ml of PBS.  The femurs were then infused with PBS 
containing 50mg/ml of type IV collagenase (C5138, Sigma) and incubated at 370C for 15 
minutes.  The collagenase-treated femurs were flushed again with PBS and cells pooled 
with the first flush fraction.  Finally, the “empty” femurs were directly flushed with 1 ml 
of Trizol, to recover RNA from cells firmly adherent to the bone matrix.  The flushed 
cells were incubated with fluorescein isothiocynate (FITC)-conjugated CD45 antibody 
and with the following panel of phycoerythrin (PE)-conjugated lineage-restricted 
antibodies: Gr-1 (granulocytes), B220 (B-lymphocytes), CD3e (T-lymphocytes), and Ter-
119 (erythroid cells) (all antibodies from Pharmingen, San Diego, CA).  Cells were sorted 
on a MoFlo high speed flow cytometer (Dako Cytomation, Fort Collins, CO).  CXCL12 
and β-actin mRNA were measured by quantitative real time RT-PCR.  To estimate the 
total CXCL12 mRNA contribution of each fraction, the number of cells in each fraction 
was multiplied by the amount of CXCL12 mRNA relative to β-actin mRNA found in that 
fraction.  The number of cells in the Trizol-flushed fraction was estimated using β-actin 
mRNA expression and was based on a standard curve showing that the level of β-actin 
mRNA correlated in a linear fashion with cell number (data not shown).  
Stromal cell fractionation.  Femora, tibiae and iliac crests were cleaned 
thoroughly to remove associated muscle tissue and then crushed in a mortar and pestle to 
 37 
release the marrow.  Bone fragments were collected by filtration through a 40 µm cell 
strainer (BD Biosciences, San Jose, CA) and washed extensively in PBS with 2% FCS to 
remove non-adherent bone marrow cells.  The bone fragments were further minced with a 
scalpel and then incubated at 370C with a 3mg/ml solution of Type I collagenase 
(Worthington, Lakewood NJ) in PBS for 40 minutes in a shaking waterbath. The 
resulting population of bone derived cells was then depleted of residual hematopoietic 
cells by incubation with a cocktail of rat anti-mouse antibodies (B220, Mac-1, Gr-1, 
CD4, CD8, CD3, CD5 and Ter119) followed by incubation with anti-rat Ig coupled 
Dynabeads (Dynal Biotech, Oslo Norway).  Following lineage depletion, the cells were 
stained with a PE-conjugated anti-CD45, FITC-conjugated anti-CD31, biotinylated anti-
CD51 and streptavidin coupled allophycocyanin (all from Pharmingen).  The cells were 
separated using a FACSDiva high speed cell sorter (BD Biosciences) into three fractions: 
endothelial cells (Lin- CD45- CD31+), osteoblasts (Lin- CD45- CD31- CD51+), and 
progenitor cells (Lin-, CD45+).  The purity of the endothelial and osteoblast fractions was 
confirmed by staining for von Willebrand factor or alkaline phosphatase, respectively 
(data not shown).  Sorted cells were counted and then lysed in RNAZol (Iso-Tex 
Diagnostics, Friendswood, TX) or Trizol for RNA isolation and subsequent real time RT-
PCR analysis.   
 
Osteoblast Culture.  Murine calvarial osteoblasts were obtained using minor 
modifications of published procedures.17  In brief, calvariae were removed aseptically 
from 3-4 day old mice and incubated twice at 37oC for 10 minutes in PBS containing 
4mM EDTA and then subjected to repeated digestion for 10 minutes at 37oC with 
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200U/ml type 2 collagenase (Worthington, Lakewood, NJ) in PBS.   Products of early 
digestions were discarded, while later fractions (typically fractions 5-7) were collected by 
centrifugation and cultured in αMEM containing 10% FCS and 1% Pen/Strep.  Cells 
were cultured until 80% confluent (undifferentiated osteoblasts).  In some experiments, 
cells were then cultured in differentiation medium (αMEM containing 10% FCS, 100 
µg/ml ascorbic acid and 5mM β-glycerophosphate) for 1 week (differentiated 
osteoblasts).     
  
Histomorphometry.  Osteoblasts in the bone marrow were quantified by 
histomorphometry, as previously described.18  Briefly, femurs and tibiae were harvested, 
fixed overnight in 10% neutral formalin, decalcified by incubating in 14% EDTA at 40C 
for two weeks, and then embedded in paraffin.  To ensure that osteoclasts were excluded 
from the osteoblast count, deparaffinized sections were stained histochemically for 
tartrate-resistant acid phosphatase (TRAP) and counterstained with hematoxylin. 
Osteoblasts were counted in a blinded fashion in 4-6 200X fields per section.  In some 
cases, two sections 75 microns apart were taken from the same sample and osteoblast 
number averaged.  The number of osteoblasts per millimeter bone perimeter (N.Ob/mm) 
was calculated using the OsteoMeasure Histomorphometry System (OsteoMetrics, Inc., 
Atlanta, GA). 
 
Statistical analysis. Data are presented as mean +/- SEM or SD, as indicated in the text.  
Statistical significance was assessed using a two-sided Student’s t test.   
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2.4  RESULTS 
2.4.1  The membrane-proximal region of the G-CSFR is sufficient to mediate HPC 
mobilization.  To define the region(s) of the G-CSFR required for HPC mobilization, G-
CSF induced HPC mobilization was characterized in a series of transgenic mice 
expressing different targeted mutations of their G-CSFR (figure 1A).  The d715 G-CSFR 
mutation introduces a premature stop codon at nucleotide 2403, leading to truncation of 
the carboxy-terminal 96 amino acids of the G-CSFR.  It is representative of G-CSFR 
mutations found in approximately 35% of patients with severe congenital neutropenia.19  
Mice homozygous for the d715 G-CSFR mutation have normal basal hematopoiesis.15  In 
the d715F G-CSFR mutant, the sole remaining tyrosine (Y704) of d715 has been mutated 
to phenylalanine.  STAT-3 and STAT-5 activation by the d715F G-CSFR are markedly 
impaired.14 Homozygous d715F G-CSFR mutant mice display an isolated defect in 
granulopoiesis.14  In the GEpoR mutation, the entire cytoplasmic (signaling) domain of 
the G-CSFR is replaced with that of the erythropoietin receptor (EpoR).16  This chimeric 
receptor is predicted to bind G-CSF but transmit EpoR-specific signals. Homozygous 
GEpoR mice display peripheral neutropenia but have normal numbers of neutrophils in 
their bone marrow.16   
The G-CSFR mutant mice, all inbred on a C57BL/6 background, were treated 
with G-CSF (250 µg/kg/day x 5 days) and the number of colony forming cells (CFU-C) 
in the blood, spleen, and bone marrow measured (figure 1B).  A similar number of CFU-
C was present in the bone marrow of all mice except for G-CSF treated d715 mice, where 
a modest, but not statistically significant, increase was observed.  Compared with wild 
type mice, HPC mobilization was significantly enhanced in d715 mice.  Whereas a 15-
fold increase from baseline in blood CFU-C was observed in wild type mice, a 32-fold 
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increase was observed in d715 mice.  In contrast, HPC mobilization was severely 
impaired in GEpoR mice (1.7-fold increase in blood CFU-C from baseline), despite a 
normal number of CFU-C in the bone marrow.  d715F mice displayed an intermediate 
phenotype.  Though G-CSF induced a similar rise in blood and spleen CFU-C, the 
number of CFU-C in the bone marrow of d715F mice was significantly increased 
compared with wild type mice.  Similar results were observed after treating mice with 
100 µg/kg/day G-CSF for 5 days (data not shown).  These data show that the membrane-
proximal 87 amino acids of the G-CSFR are sufficient to mediate G-CSF-induced HPC 
mobilization.  Moreover, these data show that the signals generated by the GEpoR are not 
able to substitute for those of the G-CSFR to induce HPC mobilization.   
 
2.4.2  Down-regulation of CXCL12α protein expression is a key event in G-CSF 
induced HPC mobilization.  Accumulating evidence suggests that CXCL12/CXCR4 
signaling may be a key regulator of HPC trafficking in the bone marrow.  We and others 
previously showed that CXCL12α protein expression in the bone marrow decreases 
during G-CSF-induced HPC mobilization.10-12 To extend these findings, we measured 
CXCL12α protein levels in the bone marrow of the G-CSFR mutant mice following G-
CSF treatment (figure 2A).  As expected, G-CSF induced a significant decrease in 
CXCL12α protein expression in the bone marrow of wild type mice.  Likewise, a 
significant decrease in CXCL12α protein expression in the bone marrow of d715 and 
d715F mice was observed.  In contrast, consistent with their impaired HPC mobilization 
phenotype, no significant change in CXCL12α protein expression was detected in 
GEpoR mice.  In fact, a highly significant correlation was observed between the degree 
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of HPC mobilization and the level of CXCL12α protein in the bone marrow  (p<.001, 
figure 2B).  
Recently, AMD3100, a selective CXCR4 antagonist capable of rapidly inducing 
HPC mobilization, was described.9  To determine whether disruption of CXCR4 
signaling could rescue the HPC mobilization defect in GEpoR mice, mice were treated 
with AMD3100 and HPC mobilization characterized.  As reported previously, in wild 
type mice, treatment with a single subcutaneous injection of AMD3100 induced a rapid 
increase in blood CFU-C that peaked 3 hours post-injection (figure 3A).8  Interestingly, a 
similar increase in blood CFU-C was observed in GEpoR mice.  Moreover, HPC 
mobilization by AMD3100 was found to be normal in G-CSFR deficient mice (data not 
shown).  These data show that AMD3100-induced HPC mobilization does not require G-
CSFR signals. Collectively, these data suggest that down-regulation of CXCL12 protein 
levels in the bone marrow is a key event in HPC mobilization induced by G-CSF. 
 
2.4.3  G-CSF regulates expression of CXCL12 mRNA in the bone marrow during 
HPC mobilization.   Whereas previous studies have focused on the proteolytic cleavage 
of CXCL12, we considered an alternative mechanism to account for the decrease in 
CXCL12 protein in the bone marrow.  We measured CXCL12 mRNA expression in the 
bone marrow during G-CSF treatment by directly flushing isolated femurs with Trizol 
reagent to ensure that RNA was recovered from all cell types in the bone marrow. Real 
time RT-PCR was performed for CXCL12 and mouse β-actin, as a control for RNA 
quality and content.  CXCL12 mRNA progressively decreased during G-CSF treatment 
reaching a nadir on day 5 when HPC mobilization is maximal and returned to normal 2 
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days after discontinuing G-CSF (figure 5A).  The decrease in CXCL12 mRNA closely 
mirrored the decrease in CXCL12α protein expression in the bone marrow (figure 5A).  
In fact, a strong correlation between CXCL12 mRNA and protein was observed (figure 
5B), suggesting that CXCL12 expression is regulated primarily at an mRNA level by G-
CSF.   
 
2.4.4  Osteoblasts are the major source of CXCL12 in the bone marrow.  Though 
controversial, current evidence suggests that CXCL12 is expressed in the bone marrow 
by osteoblasts, endothelial cells, and scattered stromal cells.5,20  Moreover, a recent report 
suggested that stem and progenitor cells may express CXCL12 at a low level.21  To 
determine which cell type(s) in the bone marrow express CXCL12 mRNA and are 
downregulated in response to G-CSF, mice were treated with G-CSF and bone marrow 
cells sorted into stromal cell (CD45-negative; lineage-negative), progenitor-enriched 
(CD45-positive; lineage-negative), and mature hematopoietic cell (lineage-positive) 
fractions (figure 5).  In addition, Trizol was directly injected into the flushed femurs to 
assess the contribution of cells remaining tightly associated with the bone matrix (“bone 
fraction” in figure 5B).  In untreated mice, the great majority of CXCL12 mRNA was 
found in the stromal cell and bone fractions (figure 5B).  Furthermore, CXCL12 
expression in these fractions was decreased by G-CSF-treatment.  These results suggest 
that stromal cells are the major source of CXCL12 in the bone marrow and are 
downregulated by G-CSF treatment.   
To define which stromal cell type(s) express CXCL12, the bone-adherent cell 
population was further fractionated into hematopoietic progenitor, mature osteoblast, and 
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endothelial cell fractions (see Methods).  Low level CXCL12 mRNA was again detected 
in the hematopoietic cell fraction (figure 5C).  Consistent with previous studies showing 
constitutive CXCL12 expression in bone marrow endothelial cells,22 a relatively high 
level of CXCL12 mRNA was detected in the endothelial cell fraction.  However, the 
highest level of CXCL12 mRNA expression was detected in the mature osteoblast 
fraction.  Relative to β-actin mRNA, mature osteoblast express 9.4-fold more CXCL12 
mRNA than endothelial cells.  These data suggest that the majority of CXCL12 in the 
BM microenvironment is produced by osteoblasts. 
 
2.4.5  G-CSF treatment potently inhibits osteoblast activity in the bone marrow.  
Surprisingly, despite the decrease in total bone marrow CXCL12 mRNA expression 
(figure 5b), on a per cell basis no significant decrease in CXCL12 mRNA was detected in 
osteoblasts isolated from mice following G-CSF treatment (figure 5C). These data raised 
the possibility that, rather than affecting SDF-1 expression per osteoblast, G-CSF 
regulated the number of osteoblasts in the bone marrow.  To explore this possibility, 
osteoblast number in the bone marrow was measured by histomorphometry.  Indeed, after 
5 days of G-CSF treatment, a striking reduction in the number of endosteal osteoblast 
was observed (figure 6 A-C).  To confirm this observation, the expression of osteocalcin, 
a specific marker of mature osteoblasts, in the bone marrow during G-CSF treatment was 
assessed (figure 6D).  Notably, osteocalcin mRNA expression was sharply reduced 
during G-CSF treatment; a 47 + 12 fold reduction in osteocalcin mRNA (relative to β-
actin mRNA) was observed in the bone marrow of G-CSF-treated mice compared with 
untreated mice.  Likewise, a significant decrease in serum osteocalcin protein was 
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detected in G-CSF treated mice (data not shown). This latter finding is consistent with a 
previous report showing that serum levels of osteocalcin decreased in patients during G-
CSF treatment.23  Collectively, these data provide strong evidence that G-CSF treatment 
potently suppresses osteoblast activity in the bone marrow.   
 We next investigated whether G-CSF could directly regulate CXCL12 expression 
in cultures of primary murine osteoblasts.  Osteoblasts were harvested from the calvariae 
of newborn mice and cultured in the presence or absence of G-CSF for 5 days.  In some 
experiments, the osteoblasts were first cultured for 1 week in the presence of ascorbic 
acid and β-glycerophosphate to induce osteoblast differentiation.  As expected, a high 
level of CXCL12 protein and mRNA expression was detected in cultures of 
undifferentiated and differentiated osteoblasts (figure 6E and data not shown).  However, 
G-CSF had no significant effect on CXCL12 expression.  Moreover, no G-CSFR mRNA 
was detected using a sensitive RT-PCR assay (data not shown).  These data suggest that 
G-CSF does not directly regulate CXCL12 expression in osteoblasts. 
 
2.5  DISCUSSION 
Clinically, G-CSF is the most widely used agent to mobilize HPC, yet the mechanisms 
mediating HPC mobilization by G-CSF are poorly understood.  To begin to define the 
region(s) of the G-CSFR that mediate this response, we characterized HPC mobilization 
by G-CSF in a series of transgenic mice carrying different targeted G-CSFR mutations.  
HPC mobilization in d715 G-CSFR mice is significantly enhanced compared with wild 
type mice, suggesting the presence of an inhibitory domain in the carboxy-terminal tail of 
the G-CSFR.  Previous studies have shown that both receptor internalization24,25 and 
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activation of negative regulators of signaling (including SOC3,26 SHP-1,25 and SHIP25) 
are defective with the d715 G-CSFR.  Whether any of these signaling alterations is 
responsible for the increased mobilization response remains to be answered.  
Interestingly, the number of CFU-C in the bone marrow of G-CSF treated d715F mice is 
increased compared with G-CSF treated wild type mice, despite comparable numbers of 
the CFU-C in the blood and bone marrow.  These observations are consistent with a 
subtle defect in HPC mobilization in d715F mice.  Nonetheless, these data suggest that 
STAT 3 and STAT 5 activation by the G-CSFR is not absolutely required for HPC 
mobilization, since their activation by the d715F G-CSFR is markedly impaired.14  
Interestingly, G-CSF-induced HPC mobilization is markedly impaired in GEpoR mice, 
despite a comparable (to wild type mice) expansion in myeloid cells and HPC in the bone 
marrow.  Thus, signals generated by the chimeric GEpoR are able to efficiently transduce 
proliferative but not mobilization signals, suggesting an element of specificity in the 
mobilization signaling pathways.  Of note, these data clearly demonstrate that increases 
in bone marrow cellularity and HPC content alone are not sufficient to induce HPC 
mobilization  
Accumulating evidence suggests that CXCL12/CXCR4 signaling plays a key role 
in regulating HPC trafficking in the bone marrow.  Mice with targeted disruptions of 
CXCL12 or CXCR4 exhibit defective hematopoiesis in the bone marrow, possibly due to 
the failure of HPC to migrate from the fetal liver to the bone marrow. 7,27  Moreover, 
mice transplanted with CXCR4 deficient bone marrow cells show reduced engraftment 
and premature release of immature myeloid cells into the blood.7,27  Elevation of 
CXCL12 levels in the blood by administration of CXCL12 or by injection of an 
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adenoviral vector expressing CXCL12 is associated with a significant mobilization of 
HPC into the blood. 28,29  Conversely, treatment with AMD3100, a selective antagonist of 
CXCR4, induces rapid and robust HPC mobilization in mice and humans.8,9  Finally, we 
and others previously showed that G-CSF treatment results in a significant decrease in 
CXCL12 protein levels in the bone marrow of wild type mice. 10-12  In the present study, 
we show that CXCL12 protein levels in the bone marrow after G-CSF treatment strongly 
correlate with HPC mobilization in the G-CSFR mutant mice.  For example, the greatest 
decrease in CXCL12 protein expression in the bone marrow was observed in those mice 
displaying the most robust HPC mobilization, namely the d715 G-CSFR mice.  Perhaps 
most telling is the lack of a significant decrease in CXCL12 protein expression in the 
mobilization defective GEpoR mice (figure 2).  The availability of AMD3100, a selective 
CXCR4 antagonist, provided the opportunity to determine whether disruption of CXCR4 
signaling could rescue the mobilization defect in GEpoR mice.  Indeed, AMD3100-
induced HPC mobilization in GEpoR mice was comparable to wild type mice. 
Collectively, these data suggest that CXCL12 is an important retention signal for HPC in 
the bone marrow, and the data support a model in which disruption of CXCL12/CXCR4 
signaling is a key step in G-CSF-induced HPC mobilization.   
It is likely that multiple mechanisms contribute to the disruption of this signaling 
pathway. CD26 (dipeptidylpeptidase IV), a membrane-bound extracellular serine-
protease expressed on a subset of HPC, inactivates CXCL12 through proteolytic 
cleavage.30,31  Importantly, G-CSF induced HPC mobilization is defective in CD26 
deficient mice or in wild type mice treated with a specific CD26 inhibitor.30,31  However, 
there is no evidence showing that CD26 activity is modulated during G-CSF treatment.  
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In contrast, G-CSF treatment induces the release of a number of proteases into the bone 
marrow microenvironment, including NE, CG and matrix metalloproteinase-9 (MMP-
9).32  These proteases are able to cleave several adhesion molecules thought to play an 
important role in regulating HPC trafficking in the bone marrow, including c-Kit, 
VCAM-1, CXCR4, and CXCL12.10,11,33,34  In particular, NE and CG  are able to cleave 
and inactive CXCL12 in vitro.10,11  However, G-CSF induced HPC mobilization and 
decrease in bone marrow CXCL12 protein are normal in NE x CG deficient mice.13  
Thus, there must be efficient NE and CG-independent mechanisms to disrupt 
CXCL12/CXCR4 signaling during G-CSF induced HPC mobilization.  
As an alternative mechanism to proteolytic cleavage to regulate CXCL12 
expression, we examined the effect of G-CSF treatment on the expression of CXCL12 
mRNA in the bone marrow.  We show that G-CSF treatment induces a decrease in bone 
marrow CXCL12 mRNA that mirrors the fall in CXCL12 protein.  In fact, a strong 
correlation between CXCL12 protein and mRNA levels in the bone marrow was 
observed.  This decrease in CXCL12 mRNA is not simply due to the dilution of 
CXCL12-expressing cells in the bone marrow during G-CSF treatment, since no 
significant decrease in CXCL12 mRNA was observed in GEpoR mice, despite a similar 
expansion of myeloid cells in the bone marrow.  These data suggest that during G-CSF 
induced HPC mobilization, CXCL12 expression in the bone marrow is primarily 
regulated at the mRNA level.  
 The mechanism by which G-CSF regulates CXCL12 mRNA expression in the 
bone marrow is an important unanswered question.  In particular, the cell type(s) in the 
bone marrow that express CXCL12 and are regulated during G-CSF treatment are 
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unknown.  One report suggested that CXCL12 is primarily expressed by osteoblasts, 
endothelial cells, and scattered stromal cells in the mesenchyme.5  In contrast, Ara and 
colleagues, using a transgenic mouse in which the green fluorescent protein gene was 
inserted into the CXCL12 gene locus, reported that endothelial cells and osteoblasts in 
the bone marrow did not constitutively express CXCL12.35 Finally, a recent report 
suggested that a subset of hematopoietic progenitors produce a small amount of 
CXCL12.21   
To address this question, we quantified CXCL12 mRNA expression in sorted 
bone marrow populations of mature hematopoietic cells, progenitor cells, and stromal 
cells.  These data confirm that progenitor cells, defined as CD45-positive lineage-
negative cells, express a low level of CXCL12.  Given the low level of expression and the 
relative scarcity of these cells, it is unlikely that hematopoietic progenitor cells contribute 
significantly to the bulk production of CXCL12 in the bone marrow.  Nonetheless, it is 
possible that CXCL12 expression by progenitor cells may significantly regulate the 
trafficking of progenitors cells through an autocrine or paracrine mechanism; further 
study is needed to address this possibility.  On the other hand, bone marrow stromal cells 
appear to be the major source of CXCL12 in the bone marrow. Within the stromal cell 
fraction, endothelial cells and mature osteoblasts express significant CXCL12 mRNA.  
Based on the high level of CXCL12 expression per cell and the relative abundance of 
osteoblasts within the bone marrow stromal cell fraction, we conclude that osteoblasts are 
the major source of CXCL12 in the bone marrow. Interestingly, CXCL12 mRNA 
expression per osteoblast did not change during G-CSF treatment.  Rather, G-CSF 
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appears to regulate CXCL12 mRNA expression in the bone marrow by decreasing 
osteoblast number. 
 There is accumulating evidence that osteoblasts play a key role in establishing and 
maintaining the stem cell niche in the bone marrow.20,36,37 In addition to CXCL12, 
osteoblasts express several genes thought to be important for stem cell function, 
including the notch ligand Jagged-1,37 a number of hematopoietic growth factors ( e.g., 
G-CSF),38  angiopoietin,39 and N-cadherin.36   Herein, we show that G-CSF potently 
inhibits mature osteoblast activity in the bone marrow.  After 5 days of G-CSF treatment, 
mature osteoblast number in the bone marrow was reduced at least 3-fold.  Moreover, 
osteocalcin mRNA expression in the bone marrow was reduced nearly 50-fold.  The 
magnitude of the change in osteocalcin expression compared with the change in 
osteoblast number in the bone marrow suggests that G-CSF may regulate both osteoblast 
number and activity.  Intriguingly, patients treated long term with G-CSF develop marked 
osteopenia.40  In addition, transgenic mice overexpressing G-CSF develop osteopenia.41,42  
Collectively, these data raise the possibility that G-CSF, by regulating osteoblast 
function, may have profound effects on the stem cell niche that ultimately contribute to 
HSC mobilization.    
 We previously showed by analysis of bone marrow chimeras between G-CSFR 
deficient and wild type mice that G-CSFR expression on bone marrow stromal cells was 
neither necessary nor sufficient to mediate G-CSF-induced hematopoietic progenitor cell 
mobilization.4  Consistent with this finding, in the present study we show that cultured 
primary osteoblasts do not express detectable G-CSFR using a sensitive RT-PCR assay.  
Moreover, G-CSF does not modulate CXCL12 expression in primary osteoblast cultures.  
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Together, these data provide compelling evidence that G-CSF regulates osteoblast 
CXCL12 through an indirect mechanism.   
In summary, this study provides additional evidence that strongly supports a 
model in which disruption of CXCL12/CXCR4 signaling is a key event in G-CSF 
induced HPC mobilization. Osteoblasts appear to be the major source of CXCL12 
production in the bone marrow.  G-CSF treatment potently inhibits osteoblast activity in 
the bone marrow, thereby reducing CXCL12 expression. These data suggest a model 
(figure 7) in which G-CSF initiates the mobilization cascade by stimulating a, as yet 
unidentified, G-CSFR expressing cell population in the bone marrow.  These cells then 
generate a trans-acting signal that suppresses osteoblast activity and, in particular, 
CXCL12 expression.  The consequent decrease in CXCR4 signaling in hematopoietic 
progenitor cells then enhances their migration from the bone marrow, through unclear 
mechanisms.  A better understanding of the mechanism by which G-CSF regulates 
CXCL12 mRNA expression may lead to the development of improved clinical protocols 
for stem cell mobilization in patients. 
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2.7  FIGURE LEGENDS 
Figure 2.1  G-CSF-induced HPC mobilization in G-CSFR mutant mice.  A.  
Schematic of targeted G-CSF receptor mutations.  Cytoplasmic tyrosines (Y) and the 
conserved box 1 and box 2 motifs are indicated.  In the d715F mutant, the sole remaining 
tyrosine (Y704) of the G-CSFR has been mutated to phenylalanine (F).  B. Tissue 
distribution of HPC following G-CSF treatment.  Wild type (WT) and G-CSFR mutant 
mice (n=4, each) were treated with G-CSF (250 µg/kg/day) for 5 days and the number of 
CFU-C in blood, spleen, and bone marrow quantified 4 hours after the final dose of G-
CSF.  Data represent the mean +/- SD.  *P < 0.05 compared with G-CSF treated wild type 
mice. 
Figure 2.2  CXCL12α protein expression in the bone marrow following G-CSF 
treatment.  A. G-CSFR mutant mice (n=7, each) were treated with G-CSF (100 
µg/kg/day) for 5 days and the amount of CXCL12α protein in the bone marrow 
extracellular fluid measured by ELISA. Data represent the mean +/- SD.  *p < 0.05 
compared with untreated mice of the same genotype.  B. Plot of CXCL12α protein in the 
bone marrow versus the log of number of CFU-C in the blood on day 5 of G-CSF 
treatment (p<.001).   
Figure 2.3  AMD3100 mobilization in GEpoR mice.  Mice were treated with a single 
subcutaneous injection of AMD3100 (5 mg/kg).  The number of CFU-C in the blood was 
measured over a 6 hour period (n=3-4, each time point).  Data represent the mean +/- SD.  
Figure 2.4  CXCL12 mRNA expression during G-CSF-induced HPC mobilization.  
A. Wild type mice were treated with G-CSF (100 µg/kg/day) for 5 days followed by a 2-
day recovery period.  The number of CFU-C in the blood (upper panel) and CXCL12 
protein expression in bone marrow extracellular fluid (middle panel) were measured at 
the indicated time points (n=2, each).   CXCL12 mRNA expression in the bone marrow 
was measured by directly flushing femurs with Trizol and performing real time RT-PCR 
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on the recovered RNA.  Shown is the relative amount of CXCL12 mRNA compared with 
β-actin mRNA (lower panel).   B. Plot of CXCL12α protein versus CXCL12 mRNA 
(r2=0.56, p<.02).  C. Wild type and GEpoR mice (n=6, each) were treated with G-CSF for 
5 days and CXCL12 mRNA quantified.  Data represent the mean +/- SD.  *p < 0.05 
compared with day 0 or untreated mice. 
Figure 2.5  Regulation of bone marrow stromal cell activity during G-CSF induced 
HPC mobilization.  A. Bone marrow cells were recovered from the femurs and tibiae of 
mice by flushing and collagenase treatment and then sorted into the indicated cell 
populations based on CD45 and lineage expression.  Shown is a representative histogram.  
B. To examine cells firmly adherent to the bone matrix, the flushed femurs were injected 
with Trizol to obtain the “bone fraction”.  Total CXCL12 mRNA in each cell population 
was estimated by multiplying the measured CXCL12 mRNA by the cell number in each 
cell fraction; the number of cells in the bone fraction was estimated based on β-actin 
mRNA levels.  *p<.05.  C. Cells harvested from the bone fraction were sorted into the 
indicated cell populations (see Methods) and CXCL12 mRNA expression relative to β-
actin expression measured.  Data represent the mean + SEM. 
Figure 2.6  G-CSF inhibits osteoblast activity in the bone marrow.  Wild type mice 
were treated with G-CSF (125 µg/kg twice daily for 5 days) and osteoblast activity 
assessed (A-D).  A&B. Representative photomicrographs showing endosteal osteoblasts 
(arrows) in untreated (A) or G-CSF treated mice (B).  Original magnification x 400.  C. 
Quantification of osteoblast number by histomorphometry.  Shown are the number of 
osteoblasts (N.Ob) per mm of bone perimeter.  D. Bone marrow osteocalcin mRNA 
expression. Total bone marrow RNA was obtained by directly flushing femurs with 
Trizol.  The expression of osteocalcin mRNA relative to β-actin mRNA is shown.  E. 
Primary osteoblasts were cultured in the presence of 100 ng/ml of G-CSF for the 
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indicated time and CXCL12 mRNA quantified.  Data represent the mean +/- SEM.  
*p<.05.   
Figure 2.7  Model of G-CSF induced HPC mobilization.  Osteoblasts constitutively 
produce large amounts of CXCL12, providing an important retention signal for HPC 
in the bone marrow.  G-CSF initiates the mobilization cascade by stimulating a 
population of G-CSFR+ cells in the bone marrow.  These cells, in turn, negatively 
regulate osteoblast number and activity, resulting in decreased CXCL12 expression in 
the bone marrow.  The consequent decrease in CXCR4 signaling in HPC leads to their 
migration from the bone marrow to blood.  
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SUPPRESSION OF CXCL12 PRODUCTION BY BONE MARROW 
OSTEOBLASTS IS A COMMON AND CRITICAL PATHWAY FOR 
CYTOKINE-INDUCED MOBILIZATION 
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3.1 ABSTRACT 
 
     Numerous molecular mechanisms have been implicated in G-CSF-induced 
mobilization, including the induction of bone marrow proteases, attenuation of adhesion 
molecule function, and disruption of CXCL12/CXCR4 signaling in the bone marrow.  In 
addition, recent reports suggest that a decrease in number of CXCL12-producing 
osteoblasts may play a role in this latter mechanism.  However, little is known about 
extent to which these mechanisms overlap or function independently of each other.  
Similarly, it is unclear to what extent mobilizing cytokines besides G-CSF may share 
common mechanisms.  To begin to address these questions we asked whether other 
mobilizing agents from the hematopoietic cytokine family operate through the 
CXCL12/CXCR4 pathway.  Treatment with G-CSF, Flt3L, and SCF resulted in 
downregulation of CXCR4 surface expression and function on mobilized c-Kit positive, 
lineage negative cells and loss of bone marrow CXCL12 protein and mRNA.  Isolating 
and sorting bone marrow stromal cells demonstrated that the loss of CXCL12 expression 
occurred in the osteoblast—but not non-osteoblast—fraction, suggesting a central role for 
osteoblasts in mediating mobilization.  Next, to investigate the relationship between 
various mechanisms of mobilization, we studied G-CSF-induced mobilization in mice 
genetically deficient in CXCR4.  G-CSF treatment led to induction of bone marrow 
metalloproteinases in CXCR4 null bone marrow chimeras, but surprisingly did not 
increase the number of circulating hematopoietic progenitors.  In contrast, treatment with 
a small molecule antagonist of adhesion molecule Very late antigen 4 (VLA-4/α4β1 
integrin) doubled the number of circulating progenitors.  Together, these results suggest 
that CXCL12/CXCR4 signaling—featuring significant loss of CXCL12 expression by 
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osteoblasts—plays a central role in cytokine-induced mobilization, and that accessory 
mechanisms such as induction of proteases and downregulation of adhesion molecules 
must function upstream or downstream of CXCL12/CXCR4 signaling. 
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3.2 INTRODUCTION 
     Under normal circumstances, hematopoiesis is regulated such that immature 
hematopoietic stem and progenitor cells (HSPC) are restricted to the bone marrow and 
are rarely observed in peripheral blood.   Under certain circumstances, however, this 
regulation is loosened and significant numbers of HSPC are released to the circulation, a 
process termed “mobilization.”  Mobilization can be induced pharmacologically by a 
wide range of agents, including hematopoietic cytokines, chemokines, and cytotoxic 
drugs.  These agents mobilize HSPC to different degrees and with varying kinetics, 
raising the possibility that several distinct mechanisms may exist by which mobilization 
may occur. 1,2. On the other hand, as certain subsets of mobilizing agents work with 
similar kinetics, the possibility remains that mobilizing agents within a molecular family 
may share common mechanism of mobilization.  For example, virtually all hematopoietic 
cytokines studied require 5-7 days for maximum mobilization.3-7  However, common 
mechanisms in cytokine-induced mobilization have yet to be identified. 
     The best characterized and most widely used mobilizing agent is Granulocyte-colony 
stimulating factor (G-CSF).8  To date, three general mechanisms have been implicated in 
G-CSF-induced mobilization (reviewed in 2,9).  First, G-CSF treatment leads to 
downregulation in the bone marrow of serpin family protease inhibitors as well as 
upregulation of neutrophil-derived proteases neutrophil elastase (NE), cathepsin G (CG), 
and metalloproteinase 9 (MMP9).10,11  The net induction of proteolysis in the bone 
marrow may contribute to cell migration by facilitating degradation of extracelluar matrix 
(ECM) and enhancing cleavage of key signaling molecules.12-15  
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     Second, G-CSF treatment is believed to disrupt mechanisms that cause bone marrow 
retention of HSPC at steady state, notably the interaction between vascular cell adhesion 
molecule 1 (VCAM-1) and very late antigen 4 (VLA-4/α4β1 integrin). 16-18     
     Finally, accumulating evidence suggests that signaling between CXCL12, a 
chemokine expressed by bone marrow stroma, and its receptor CXCR4, expressed by 
HSPC, plays an important role in mobilization.  Irradiated mice reconstituted with 
CXCR4 deficient bone marrow have at baseline a high number of circulating HSPC.19  
Further, bone marrow levels of SDF-1 protein and mRNA fall during G-CSF treatment, 
and mobilized HSPC express lower levels of functional CXCR4.12,13,20  Together, these 
findings suggest that the disruption of CXCL12/CXCR4 signaling leads to the loss of a 
key retention signal for bone marrow HSPC.  
     Of note, the three primary mechanisms involved in G-CSF-induced mobilization—
induction of proteases, downregulation of adhesion molecules, and CXCL12/CXCR4 
disruption—likely interact at several levels.  For example, upregulation of bone marrow 
proteases is believed to contribute to cleavage of bone marrow CXCL12 as well as 
adhesion molecules VCAM-1 and c-Kit during G-CSF-induced mobilization.12,21,22   
Similarly, CXCL12 signaling contributes to HSPC adhesion to fibronectin coated plates, 
suggesting that adhesion molecule disruption may occur at least in part downstream of G-
CSF-induced CXCL12/CXCR4 disruption in vivo.23  These findings raise the possibility, 
therefore, that disruption of CXCL12/CXCR4 signaling represents the primary 
mechanism by which G-CSF induces mobilization and that other mechanisms—i.e. 
induction of bone marrow proteases and downregulation of adhesion molecules—operate 
upstream or downstream within this pathway.     
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     Recently, our lab and others have reported that G-CSF treatment is associated with a 
decrease in the number of mature osteoblasts in the bone marrow.20,24  As osteoblasts are 
thought to be a source of CXCL12 in the bone marrow, this observation suggests that G-
CSF-induced loss of osteoblasts plays a role in mobilization.  On the other hand, other 
cell types express CXCL12, notably endothelial cells and CXCL12-abundant reticular 
(CAR) cells.25,26 Indeed, several recent reports question whether osteoblasts produce 
significant amounts of CXCL12, raising the possibility that the loss of osteoblasts 
represents a coincidental finding unique to G-CSF treatment and does not play a role in 
mobilization. 26,27 
     In this study we undertook to integrate recent findings concerning mechanisms of 
HSPC mobilization by focusing on one well-described mechanism.  Specifically, we 
hypothesized that loss of osteoblast-produced CXCL12 is a common and critical 
mechanism in cytokine-induced HSPC mobilization.  Accordingly, we investigated 
whether loss of osteoblasts was a common finding in cytokine-induced mobilization and 
whether loss of osteoblasts per se could account for the overall decline in bone marrow 
CXCL12.  Next, we sought to determine the relative importance of disruption of CXCR4 
signaling compared to other mechanisms known to be involved in mobilization—namely, 
the induction of bone marrow proteases and downregulation of VCAM-1/VLA-4 
interactions—by studying mobilization in mice genetically deficient in CXCR4.  In this 
way, we tried to define whether these separate pathways contribute to mobilization 
individually or co-operate within the same mobilizing pathway. 
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3.3  MATERIALS AND METHODS 
 
Mice.  Wild type (Ly5.1), CXCR4 +/- (Ly5.2, provided by K. Weilbaecher, Washington 
University School of Medicine), and pOBCol2.3-GFP (gift of D. Rowe, University of 
Connecticut) were on the C57BL/6 strain.  Mice were housed in a specific pathogen-free 
environment in accordance with the Washington University Animal Studies Committee. 
 
Fetal Liver Transplantation. Fetal livers were harvested from embryonic day 14–16 
embryos generated by setting up timed pregnancies between CXCR4+/– mice. Single-cell 
suspensions were frozen in RPMI medium 1640 with 20% FCS and 20% DMSO (Sigma, 
St Louis, MO). A portion of the embryo was saved to determine genotype by PCR. 6-12 -
week-old C57BL/6 Ly5.1 recipients were lethally irradiated by using a 137Cs source with 
900 rads. Single-cell suspensions of 5x106 CXCR4–/– or WT thawed fetal liver cells 
were injected into the lateral tail vein of each recipient mouse to generate CXCR4–/– 
mice and WT controls.  
 
Mobilization protocols.  G-CSF, Flt-3 ligand (Flt3L), and SCF.  Recombinant human 
G-CSF, Flt3L, or SCF (Amgen, Thousand Oaks, CA) diluted in phosphate-buffered 
saline (PBS) with 0.1% low endotoxin bovine serum albumin (Sigma, St. Louis MO) was 
administered by daily subcutaneous injection at a dose of 250 µg/kg (G-CSF), 10 
ug/mouse (Flt3L), or 4 ug/mouse (SCF) for 7 days.  Mice were analyzed 3-4 hours after 
the final cytokine dose.  AMD15057.  AMD15057, a generous gift from AnorMED Inc. 
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(British Columbia, Canada), was reconstituted to a final concentration of .2mg/ml in 
sterile 10:36:54 ethanol:propylene glycol:water and administered as a single intravenous  
injection at a dose of 1 mg/kg.  Mice were analyzed 3 hours post-injection.   
 
Peripheral Blood and Bone Marrow Analysis.  Blood was obtained by retroorbital 
venous plexus sampling in polypropylene tubes containing EDTA.  Bone marrow cells 
were isolated by flushing femurs and tibias with 3-5ml cold PBS.  Bone marrow 
extracellular fluid was obtained by flushing each femur with 1 ml of ice-cold PBS 
without serum, and the supernatant was harvested after centrifugation at 400 x g for 3 
minutes. 
 
Metalloproteinase Activity.  Extracellular fluid was isolated as above.  100ul of each 
sample was assayed for metalloproteinase activity using the EnzChek Gelatinase kit with 
DQ Gelatin from pig skin, fluorescein conjugate substrate (Molecular Probes) according 
to manufacturers’ instructions. 
 
CXCL12 ELISA.  Quantification of CXCL12 protein in bone marrow extracellular fluid 
was performed using commercially available ELISA kit (R&D Systems, Minneapolis, 
MN) according to manufacturers’ instructions using 50ul undiluted sample.   
 
Colony-forming cell assay.  Blood, bone marrow, and spleen cells were harvested from 
mice using standard techniques and the number of nucleated cells in these tissues 
quantified using a Hemavet automated cell counter.  We plated 7-35 µl blood, 1 x 105 
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nucleated spleen cells, or 2.0 x 104 nucleated bone marrow cells in 2.5 ml 
methylcellulose media supplemented with a cocktail of recombinant cytokines 
(MethoCult 3434; Stem Cell Technologies, Vancouver, British Columbia, Canada).  
Cultures were plated in duplicate and placed in a humidified chamber with 6% carbon 
dioxide (CO2) at 37° C.  Colonies containing at least 50 cells were counted on day 7 of 
culture. 
 
Real-time quantitative RT-PCR.  Femurs were flushed with a total of 2 ml Trizol 
reagent (Invitrogen, Carlsbad, CA) and RNA was isolated according to the 
manufacturer’s instructions and resuspended in 150 µl RNase/DNase free water.  
Quantitative Real-time reverse transcriptase-polymerase chain reaction (Q-RT-PCR) was 
performed using the TaqMan One-step RT-PCR Master Mix Reagents Kit (Applied 
Biosystems, Foster City, CA) on a GeneAmp 7300 Sequence Detection System (Applied 
Biosystems).  The reaction mix consisted of 5 µl RNA, 12.5 µl RT-PCR reaction mix, 
200 nM forward primer, 200 nM reverse primer, 280 nM internal probe, and .625 µl 
Multiscribe reverse transcriptase and RNase inhibitor in a total reaction volume of 25 µl.  
Reactions were repeated in the absence of reverse transcriptase to confirm that DNA 
contamination was not present.  RNA content was normalized to murine β-actin.  PCR 
conditions were 48°C for 30 minutes and 95°C for 10 minutes, followed by 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute.   
CXCL12 forward primer: 5′-GAGCCAACGTCAAGCATCTG–3′;  
CXCL12 reverse primer: 5′-CGGGTCAATGCACACTTGTC–3′;  
CXCL12 dT-FAM/TAMRA probe: 5′-TCCAAACTGTGCCCTTCAGATTGTTGC–3′;  
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β-actin forward primer: 5′- ACCAACTGGGACGATATGGAGAAGA–3′;  
β-actin reverse primer: 5′- TACGACCAGAGGCATACAGGGACAA–3′;  
β-actin dT-FAM/TAMRA probe: 5′- AGCCATGTACGTAGCCATCCAGGCTG–3′. 
 
 
CXCR4 cell surface expression.  Bone marrow and peripheral blood cells were 
recovered from control and cytokine treated mice as described above.  The flushed cells 
were incubated with the following panel of fluorescein isothiocynate (FITC)-conjugated 
lineage-restricted antibodies: Gr-1 (granulocytes), B220 (B-lymphocytes), CD3e (T-
lymphocytes), and Ter-119 (erythroid cells), with allophycocyanin (APC)-conjugated 
anti-c-Kit antibody  and a biotinylated anti-CXCR4 antibody followed by incubation with 
phycoerythrin (PE)-conjugated streptavidin (all antibodies eBiosciences, San Diego, CA, 
except anti-CXCR4 from BD Pharmingen)  Cells were analyze on a FACScan flow 
cytometer (Becton Dickenson).   
 
Histomorphometry.  Osteoblasts in the bone marrow were quantified by 
histomorphometry, as previously described.20  Briefly, femurs and tibiae were harvested, 
fixed overnight in 10% neutral formalin, decalcified by incubating in 14% EDTA at 40C 
for two weeks, and then embedded in paraffin.  To ensure that osteoclasts were excluded 
from the osteoblast count, deparaffinized sections were stained histochemically for 
tartrate-resistant acid phosphatase (TRAP) and counterstained with hematoxylin. 
Osteoblasts were counted in a blinded fashion in 4-6 200X fields per section.  In some 
cases, two sections 75 microns apart were taken from the same sample and osteoblast 
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number averaged.  The number of osteoblasts per millimeter bone perimeter (N.Ob/mm) 
was calculated using the OsteoMeasure Histomorphometry System (OsteoMetrics, Inc., 
Atlanta, GA). 
 
Isolation of osteoblast lineage cells by flow cytometry.  Bone marrow cells were 
recovered from the femurs of pOBCol2.3-GFP mice by flushing with PBS. The femurs 
were then infused with PBS containing 50 mg/mL type II collagenase (Worthington 
Biochemical) and incubated at 37°C for 15 minutes. The collagenase-treated femurs were 
flushed again with PBS, cells pooled, and the process repeated for a total 6 digests.  Pilot 
experiments demonstrated that virtually all recoverable GFP positive cells were found in 
these 6 digests (data not shown). 
     To isolate osteoblast lineage and non-osteoblast cells, pooled fractions were stained 
with PE-conjugated anti-mouse CD45 and anti-mouse Ter119 antibodies (eBiosciences).  
CD45-, Ter119-, GFP+ (osteoblast) and GFP- (non-osteoblast) cells were sorted directly 
into TRIZOL using a MoFlo high-speed cell sorter (Dako). RNA was subsequently 
isolated and Q-RT-PCR performed as above 
In situ hybridization.  In situ hybridization using a probe for CXCL12 was performed on 
deparaffinized sections from mouse long bones as described previously, using 35S-labeled 
riboprobes28 and counterstained with toluidine blue.   
Statistical analysis. Data are presented as mean +/- SEM.  Statistical significance was 
assessed using a two-sided Student’s t test.   
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3.4  RESULTS 
3.4.1  Loss of osteoblast-produced CXCL12 is a common finding in cytokine-
induced mobilization.  The disruption of CXCL12/CXCR4 signaling is known to be one 
mechanism by which G-CSF treatment induces HSPC mobilization.  Bone marrow levels 
of CXCL12 protein and mRNA fall during treatment and CXCR4 surface expression on 
mobilized cells is diminished, possibly through proteolytic cleavage of the extracellular 
portion of the receptor.13 Of note, this process requires 5 days to reach maximum HSPC 
mobilization, which mirrors the kinetics of the decline in osteoblast number.(20 and MJC, 
DCL, unpublished data)  As other hematopoietic cytokines—but not chemokines—
require this lengthy period to induce mobilization, we reasoned that this mechanism 
might prove to be a common pathway by which cytokines induce HSPC mobilization.  
Accordingly, we treated mice with two hematopoietic cytokines, Flt3 ligand (Flt3L) and 
stem cell factor (SCF) as well as G-CSF.  Bone marrow levels of CXCL12 protein and 
mRNA were measured by ELISA and quantitative real time PCR, respectively.  All three 
cytokines induced a robust mobilization (Figure 1A top).  Numbers of HSPC mobilized 
by each agent was similar when the proliferative effect of Flt3L treatment on progenitors 
is taken into account. (Figure 1A bottom)  Bone marrow CXCL12 protein and mRNA 
was reduced to a similar extent after mobilization with all three agents (Figure 1B).   
     Since some reports suggest that CXCR4 function in HSPC is attenuated with G-CSF 
treatment, both CXCR4 surface expression and function was compared between HSPC 
from mice treated with G-CSF, Flt3L, and SCF.  First, CXCR4 surface expression was 
measured by flow cytometry, gating on c-Kit positive, lineage negative (KL) cells in 
mobilized blood and bone marrow.  Consistent with previous reports, CXCR4 expression 
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was decreased in G-CSF-mobilized versus bone marrow KL cells.  A similar decrease 
was noted in KL cells in Flt3L but not SCF treated peripheral blood cells (Figure 1C).  
Next, CXCR4 function on mobilized peripheral HSPC was measured by comparing 
migration of peripheral blood versus bone marrow CFU-C toward CXCL12 in a transwell 
assay.   CFU-C derived from Flt3L- or SCF-mobilized peripheral blood failed to migrate 
as well as bone marrow CFU-C from these mice, suggesting that downregulation of 
CXCR4 function plays a role in HSPC mobilization (Figure 1D).   
     Since loss of osteoblasts, a source of CXCL12 in the bone marrow, was observed with 
G-CSF treatment, we hypothesized that the decrease in CXCL12 mRNA and protein 
observed after Flt3L and SCF treatment resulted from a similar decrease in osteoblast 
number.  Standard histomorphometry performed on H&E-stained paraffin sections from 
matched mice treated with G-CSF, Flt3L, and SCF confirmed a decrease in osteoblast 
surface and number (Figure 1E and data not shown.) 
     Taken together, these findings suggest that disruption of CXCL12/CXCR4 
signaling—featuring a significant loss in CXCL12-expressing osteoblasts—is a common 
feature of cytokine-mediated HSPC mobilization. 
 
3.4.2  Loss of bone marrow CXCL12 results specifically from loss of bone marrow 
osteoblasts.  As noted above, several cell types in the bone marrow express CXCL12, 
including osteoblasts, endothelial cells, and CAR cells.  Our previous results demonstrate 
a loss in total bone marrow CXCL12 mRNA and protein with an associated loss of 
histologically identifiable osteoblasts in mice treated with each of the cytokines tested, G-
CSF, Flt3L and SCF.  However, as some controversy exists as to the contribution of 
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osteoblast-expressed CXCL12 to total bone marrow CXCL12, we inquired whether loss 
of osteoblast CXCL12 specifically was associated with cytokine induced mobilization.  
First, CXCL12 in situ hybridization was performed on paraffin sections from mice 
treated with G-CSF or untreated.  At baseline, CXCL12 mRNA is detected both on 
endosteal and trabecular bone surfaces (Figure 2A left panel, arrows) as well as in the 
bone marrow proper (arrowheads).  After G-CSF treatment, abundant scattered cells in 
the bone marrow continue to express CXCL12, while CXCL12 expression disappears 
from bone surfaces, suggesting that specifically osteoblast CXCL12 is targeted during G-
CSF treatment.   
     To confirm this finding in a more quantitative manner, we utilized transgenic mice 
expressing GFP under control of a 2.3 kb fragment of the collagen I promoter.  These 
mice express GFP in osteoblast lineage cells, including mature osteoblasts, bone lining 
cells, and osteocytes.29  As shown in representative FACS plots, which are gated on 
CD45 negative, Ter119 negative cells, the stromal cell compartment can be divided into 
the GFP positive osteoblast lineage and GFP negative stromal fractions, which would be 
expected to include both endothelial and CAR cells (Figure 2B).  As expected, the GFP 
positive fraction was highly enriched for osteoblast markers osteocalcin, osteoprotegerin, 
and Runx2 (data not shown).  Mice were treated with G-CSF or Flt3L, osteoblasts and 
stromal cells were isolated and CXCL12 mRNA was measured in each fraction.  Fewer 
GFP positive cells were observed in cytokine treated mice versus controls, consistent 
with the loss of osteoblasts observed histologically (data not shown).  Within the 
remaining GFP positive population, CXCL12 mRNA was markedly reduced with respect 
to beta actin.  Importantly, no reduction in CXCL12 mRNA in the stromal fraction was 
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noted.  Together, these results suggest that loss of osteoblast-produced CXCL12 may 
represent a common pathway in cytokine-induced mobilization.  
 
3.4.3  G-CSF-induced increase in bone marrow metalloproteinase activity does not 
depend on CXCR4 signaling.  Next, to begin to address the relationship of 
CXCL12/CXCR4 signaling disruption with other known mechanisms involved in 
mobilization—induction of proteolytic microenvironment, and attenuation of integrin 
function—we tested whether the upregulation of bone marrow proteolytic activity seen 
during G-CSF treatment is dependent on disruption of CXCR4 signaling or is activated 
independently.  To this end, protease activation was tested in mice deficient in CXCR4 
signaling.  CXCR4 null bone marrow chimeras were generated by transplanting Ly5.2 
CXCR4 knockout or wild type fetal liver cells into irradiated Ly5.1 recipients.  Only 
recipients that reconstituted with greater than 90% peripheral blood chimerism were 
analyzed (data not shown).  CXCR4 deficient and wild type chimeras were treated with 
G-CSF, bone marrow plasma was isolated and tested for metalloproteinase activity by 
measuring fluorescence released by cleavage of labeled gelatin.  Consistent with previous 
reports, G-CSF increased metalloproteinase activity in the bone marrow of treated wild 
type mice (Figure 3A).   A similar trend was seen in CXCR4 null chimeras (Figure 3B), 
indicating that bone marrow metalloprotease activation does not depend on CXCR4 
signaling. 
 
3.4.4  G-CSF does not increase number of circulating HSPC in CXCR4 -/- chimeras.  
Next we tested the relative importance of disruption of CXCR4 signaling compared to 
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other mobilization pathways by measuring mobilization in CXCR4 deficient chimeras.  
As mentioned above, CXCR4 deficiency at baseline leads to an elevated level of HSPC 
in both peripheral blood and spleen, emphasizing the importance of this pathway in 
progenitor cell trafficking (Figure 4A-B).  We predicted that since G-CSF treatment 
activates bone marrow proteases and disrupts function of adhesion molecules, treatment 
of CXCR4 deficient chimeras would increase the number of circulating progenitors.  
When treated with G-CSF, wild type controls mobilized normally.  Surprisingly, 
however, G-CSF treatment did not increase number of circulating progenitors in CXCR4 
null chimeras (Figure 4A-B).  This failure to mobilize does not reflect a deficiency in the 
number of bone marrow resident CFU-C, which is the same as in controls (Figure 4C) 
and is vast in comparison to the number of mobilized CFU-C.   
 
3.4.5 Treatment with a VLA-4 antagonist mobilizes HSPC in CXCR4 -/- chimeras.  
The failure of G-CSF treatment to increase the number of circulating HSPC in CXCR4 -/- 
chimeras suggests that G-CSF mobilizes primarily through the disruption of this 
signaling pathway.  An alternative possibility, however, is that CXCR4-/- chimeras at 
baseline already have maximally released their mobilizable pool of HSPC, despite the 
large progenitor pool still present in the bone marrow. 
     As a control to ensure that alternative mobilization mechanisms function normally in 
the CXCR4 null chimeras, we tested if activation of the integrin attenuation pathway 
could increase the number of circulating progenitors in these mice.  Knockout and control 
chimeras were treated with AMD15057, a small molecule inhibitor of VLA-4.  Chimeras 
transplanted with wild type cells mobilized modestly three hours after AMD15057 
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administration (Figure 5A).  CXCR4 knockout chimeras mobilized to a similar extent, 
suggesting that this pathway functions normally in CXCR4 deficient chimeras (Figure 
5B).   Taken together, these observations suggest that disruption of CXCR4 signaling is a 
necessary component of G-CSF-induced mobilization. 
 
3.5  DISCUSSION 
In recent years numerous studies have outlined mechanisms by which G-CSF treatment 
leads to the mobilization of HSPC.  These mechanisms could be integrated in two non-
mutally-exclusive models: 1) G-CSF simultaneously activates different mechanisms in 
parallel, each of which contributes individually to mobilization; and 2) G-CSF activates 
different mechanisms that lie within the same pathway and depend on each other for 
action.  Combining G-CSF treatment with AMD3100, a specific inhibitor of CXCR4 
signaling, leads to increased HSPC mobilization than with G-CSF alone, lending support 
to the former model.30  These results, however, are not definitive, since neither 
AMD3100 nor G-CSF would be expected to completely block CXCR4 signaling.  To 
address this question, therefore, we studied G-CSF-induced mobilization in a model 
where CXCR4 is genetically deleted from the hematopoietic compartment.  Surprisingly, 
G-CSF does not increase the number of circulating HSPC in this model, suggesting that 
the pleiotropic mechanisms activated by G-CSF during mobilization—specifically the 
activation of bone marrow proteases and the downregulation of adhesion molecules—
converge in the CXCL12/CXCR4 pathway (Figure 6).   
     Treatment of mice with protease inhibitors inhibits G-CSF-induced mobilization.12,13  
Protease inhibition could block G-CSF-induced mobilization upstream of 
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CXCL12/CXCR4 signaling disruption—namely, by decreasing clearance of bone 
marrow CXCL12 or inhibiting cleavage of CXCR4 from HSPC, as is reported in the 
literature—or by blocking some parallel pathway, such as inhibiting protease-dependent 
tissue migration. In CXCR4 -/- chimeras, metalloproteinase activation occurs normally 
with G-CSF treatment (Figure 3A-B), but fails to enhance mobilization, suggesting that 
the role of protease activation in G-CSF-induced mobilization is largely upstream of the 
disruption of CXCL12/CXCR4 signaling (Figure 6).  It bears noting that the role of 
proteases in G-CSF-induced mobilization is controversial, since the finding that protease 
inhibitors inhibit mobilization contrasts with findings in mice genetically deficient in 
MMP9 and neutrophil proteases, which have a normal response to G-CSF.   
     Inhibition of adhesion molecules is another mechanism by which G-CSF may induce 
HSPC mobilization.  Treatment with a VLA-4 antagonist—but not G-CSF—increases the 
number of circulating HSPC in the CXCR4 -/- chimeras (Figure 4A,5B).  This finding 
suggests that 1) inhibiting VLA-4/VCAM-1 interaction mobilizes HSPC in a CXCR4 
independent fashion; and 2) if attenuation of adhesion molecules plays a role in G-CSF-
induced mobilization, this would likely occur upstream or downstream of the disruption 
of CXCR4 signaling (Figure 6).  Little is known about what lies downstream of CXCR4 
antagonism in mobilization.  CXCR4 signaling leads to cytoskeletal reorganization, 
which may lead to changes in HSPC motility and adhesion to bone marrow stroma.31-33  
Indeed, as noted above, incubation of HSPC with CXCL12 increases adhesion to 
fibronectin in an ex vivo culture system, suggesting that modulation of adhesion 
molecules may be one way that disruption of CXCL12/CXCR4 signaling enhances HSPC 
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release from the bone marrow.23  Further work will be required to elucidate the role of 
adhesion molecules downstream of CXCR4 signaling. 
     Besides activation of bone marrow proteases, one mechanism that likely works 
upstream of the disruption in CXCL12/CXCR4 signaling is the decrease in osteoblasts 
observed in cytokine treatment.  While the role of other CXCL12-producing cells in 
maintaining supportive niches for hematopoietic stem cells remains controversial, two 
findings in this work support the hypothesis that osteoblasts specifically mediate HSPC 
mobilization.  First, loss of osteoblasts is a common finding in G-CSF, Flt3L, and SCF 
treatment.  Second, after sorting bone marrow stromal cells into osteoblastic and non-
osteoblast fractions we detected a loss of CXCL12 mRNA in the osteoblastic fraction 
only.  This finding corroborated the RNA in situ hybridization data, where G-CSF 
treatment resulted in loss of CXCL12 message on endosteal surfaces but not in the bone 
marrow itself.  One intriguing possibility is that CXCL12 loss from the endosteum but 
not from bone marrow sinusoid-associated cells results in migration of hematopoietic 
cells toward the vasculature.  This possibility will require a great deal more study.   
     Finally, it is noteworthy that several other mechanisms implicated in G-CSF-induced 
mobilization may work via osteoblasts upstream of CXCL12/CXCR4 signaling.  
Levesque and colleagues report that G-CSF treatment increases hypoxia in the bone 
marrow,34 a process which may have adverse effects on osteoblasts. 35,36  Katayama et al 
show that loss of beta adrenergic signaling inhibits G-CSF-induced HSPC mobilization 
by attenuating loss of bone marrow osteoblasts.24     
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     To summarize, our data suggest that disruption of CXCL12/CXCR4 signaling 
represents a common and critical pathway in cytokine-mediated mobilization and that 
loss of osteoblast-produced CXCL12 contributes to this effect.   
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3.7  FIGURE LEGENDS 
 
Figure 3.1  Disruption of CXCL12/CXCR4 signaling is a common feature in 
cytokine-induced mobilization.  Mice (n=6-8 each group) were treated with G-CSF, 
Flt3L, or SCF for seven days.  (A) Number of CFU-C were measured in the peripheral 
blood (top) and bone marrow (bottom) by methylcellulose colony-forming assay. 
(B)Total bone marrow CXCL12 mRNA was measured by Q-RT-PCR (top) and CXCL12 
protein in bone marrow plasma was quantified by ELISA (bottom).  (C) CXCR4 surface 
expression was compared between mobilized hematopoietic progenitors (PB) and bone 
marrow progenitors (BM) by flow cytometry gating on c-Kit positive, lineage negative 
cells in either compartment.  (D) CXCR4 function in mobilized hematopoietic 
progenitors (PB) and bone marrow progenitors (BM) was compared by measuring the 
percent of CFU-C that migrated down a gradient of CXCL12 in a transwell assay.  (E) 
Bone marrow osteoblasts were enumerated in H&E stained paraffin sections using 
standard histomorphometric technique.  Data represents mean ± SEM.  *p<.05 compared 
to control, **p<.05 compared to all other groups, ***p<.001 compared to BM. 
 
Figure 3.2  Cytokine-induced mobilization results in specific loss of osteoblast 
CXCL12.  Mice were treated with G-CSF, Flt3L, or SCF.  (A) Representative 
photomicrograph of RNA in situ from G-CSF treated (left) and untreated (right) mouse 
long bone showing CXCL12 mRNA along endosteal surface (arrows) and within bone 
marrow (BM, arrowheads).  N=2-3 each group  (B-C) Transgenic mice (n=4-5 each 
group) expressing GFP in osteoblast lineage cells (pOBCol2.3-GFP mice) were treated 
with cytokines, stromal cells were isolated and fractionated by flow cytometry into non-
osteoblast and osteoblast fractions, and CXCL12 mRNA was measured in each fraction.   
(B) representative facsplots gated on CD45 negative, Ter119 negative stromal fraction 
showing GFP positive osteoblast and GFP negative non-osteoblast fraction.  (C) CXCL12 
mRNA in GFP positive osteoblast fraction from G-CSF-treated (left) and Flt3L-treated 
(right) mice.  Data represents mean ± SEM.  *p<.05 
 
Figure 3.3  G-CSF increases bone marrow metalloproteinase activity in wild type 
and CXCR4 -/- chimeras.  Lethally irradiated chimeras (n=4 each group) reconstituted 
with CXCR4 +/+ or CXCR4 -/- fetal liver cells were treated with G-CSF and bone 
marrow plasma was isolated.  Metalloproteinase activity in the bone marrow plasma was 
estimated by measuring cleavage of fluorescently labeled substrate and normalizing for 
protein content.  Shown is metalloproteinase activity for (A) CXCR4 +/+ and (B) 
CXCR4 -/- chimeras.   Data represents mean ± SEM.  *p<.05 
 
Figure 3.4  G-CSF treatment does not increase number of circulating progenitors in 
CXCR4 -/- chimeras.  CXCR4 +/+ and -/- chimeras (n=7-10 each group) were treated 
with G-CSF and CFU-C were measured in (A) peripheral blood, (B) spleen, and (C) bone 
marrow.   Data represents mean ± SEM.  *p<.05 
 
Figure 3.5  VLA-4 antagonism increases number of circulating progenitors in 
CXCR4 +/+ and CXCR4 -/- chimeras.  CXCR4 +/+ and -/- chimeras (n=6-9 each 
group) were treated with AMD15057, a specific VLA-4 antagonist and peripheral blood 
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CFU-C were measured in (A) CXCR4 +/+ and (B) CXCR4 -/- chimeras.  Data represents 
mean ± SEM.  *p<.01 
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CHAPTER 4 
 
 
 
 
 
 
GRANULOCYTE COLONY-STIMULATING FACTOR INDUCES OSTEOBLAST 
APOPTOSIS AND INHIBITS OSTEOBLAST DIFFERENTIATION  
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4.1  ABSTRACT  
G-CSF administration results in marked decrease in bone mineral density characterized 
by increased osteoclastogenesis and loss of mature osteoblasts.  Herein, we show that the 
osteoblast decrease results from increased osteoblast apoptosis and inhibited osteoblast 
differentiation.  G-CSF acts indirectly on osteoblasts through a hematopoietic 
intermediary.  Finally, loss of osteoprotegerin (OPG) expression from mature osteoblasts 
may contribute to the increase in osteoclasts.   
 
Introduction:  Long-term treatment with G-CSF leads to a clinically significant 
osteopenia characterized by increased osteoclast activity and number.  In addition, recent 
reports have observed a decrease in number of mature osteoblasts during G-CSF 
administration.  However, neither the extent of G-CSF’s suppressive effect on the 
osteoblast compartment nor its mechanisms are well understood. 
 
Materials and methods: Transgenic mice expressing the green fluorescent protein 
(GFP) under control of the rat collagen I promoter (pOBCol2.3-GFP mice) were treated 
with G-CSF.  Osteoblast number and apoptosis were measured by flow cytometry and 
histology.  Osteoblast proliferation and turnover were assessed by labeling with BrdU.  
Bone marrow chimeras with G-CSF receptor deficient hematopoietic cells were 
generated to test whether G-CSF acts directly on osteoblast lineage cells.  
 
Results:  G-CSF administration leads to a selective loss of endosteal and trabecular 
osteoblasts; bone lining cells, osteocytes, and periosteal osteoblasts are unaffected.  
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Osteoblast turnover and apoptosis are increased.  G-CSF administration also leads to a 
significant accumulation of osteoprogenitors in the bone marrow.   The effect of G-CSF 
on osteoblasts was abrogated in wild type mice transplanted with G-CSF receptor 
deficient hematopoietic cells.  Finally, while expression of receptor activator of 
NFkappaB ligand (RANKL) in the bone marrow is relatively unaffected by G-CSF 
administration, expression of the RANKL decoy receptor, OPG, is markedly decreased.   
 
Conclusion:  G-CSF administration leads to a loss mature osteoblasts in the bone 
marrow through both an increase in osteoblast turnover and inhibition of osteoblast 
differentiation. These effects of G-CSF on osteoblasts are mediated via a hematopoietic 
intermediary.  The altered ratio of RANKL to OPG expression provides a novel 
mechanism by which G-CSF stimulates osteoclastigenesis.  
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4.2 INTRODUCTION 
Bone marrow is the normal site of both hematopoiesis and bone metabolism.  As 
predicted by their proximity, regulation of these tissues is highly integrated.  There is 
strong evidence that osteoblasts play a key role in establishing and maintaining an 
appropriate microenvironment for hematopoietic stem cells.  Conversely, the 
hematopoietic compartment is also known to regulate bone metabolism, largely through 
the production of hematopoietic cytokines [reviewed in (1), (2)].      
Granulocyte-colony stimulating factor (G-CSF) is the principal cytokine 
regulating granulopoiesis.  Long-term treatment with G-CSF is associated with 
development of clinically significant osteopenia, characterized by decreased bone mineral 
density and vertebral compression fractures (3,4).  In a recent study, the incidence of 
osteopenia in patients with severe congenital neutropenia (SCN) treated chronically with 
G-CSF was 28% (3).   Similarly, long-term exposure to G-CSF in mice leads to a 
decrease in cortical and trabecular bone, suggesting that it is G-CSF and not the 
underlying disease that is causing osteopenia in patients with SCN. (4,5)  
There is evidence that G-CSF induces osteopenia in part by stimulating osteoclast 
activity.  G-CSF treatment increases osteoclast number in the bone marrow of mice and 
increases the level of urine deoxypyridinoline in humans. (6)  Several potential 
mechanisms by which G-CSF stimulates osteoclastigenesis have been advanced.  G-CSF 
increases the proliferation of myeloid progenitors, potentially increasing the pool of 
monocytic precursors from which osteoclasts derive. (7)  In addition, G-CSF has been 
shown directly to augment osteoclast formation and activity in vitro. (8)  Nevertheless, 
the mechanisms by which G-CSF stimulates osteoclastogenesis in vivo remain undefined.     
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While long-term G-CSF treatment results in increased osteoclastogenesis, recent 
evidence suggests that short term G-CSF administration decreases osteoblast number and 
activity (6,9,10).  Our lab has shown that administration of G-CSF for 5 days in mice 
results in a marked decrease in histologically identifiable osteoblasts in the bone marrow 
and a corresponding decrease in osteocalcin mRNA.(10)  Whether this decrease in 
osteoblast number results from increased osteoblast turnover or from a defect in 
osteoblast development remains unclear.  A third possibility—that G-CSF induces 
osteoblast quiescence—was raised in a recent report by Katayama et al., who observed a 
preponderance of bone lining cells in the bone marrow of G-CSF-treated mice.(9) 
In this study, we utilize transgenic mice expressing the green fluorescent protein 
(GFP) under control of an osteoblast-lineage-specific promoter (pOBCol2.3-GFP mice) 
to measure osteoblast turnover during G-CSF administration.   We show that G-CSF 
administration leads to a selective loss of mature endosteal and trabecular osteoblasts that 
is secondary to both an increase in osteoblast apoptosis and inhibition of osteoblast 
differentiation. Bone marrow transplantation studies show that G-CSF regulates 
osteoblasts indirectly, via a hematopoietic intermediary.  Finally, we show that G-CSF 
treatment markedly decreases the bone marrow expression OPG, providing a novel 
mechanism by which G-CSF activates osteoclasts.   
4.3  MATERIALS AND METHODS. 
Mice.  The generation and characterization of pOBCol2.3-GFP mice, kindly provided by 
David Rowe at the University of Connecticut, have been described elsewhere (11).  Mice 
were maintained in a pathogen-free barrier facility in accordance with Washington 
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University Animal Studies Committee guidelines.  6-12 week old age and sex-matched 
mice were used in all studies.  
G-CSF administration. Recombinant human G-CSF, a generous gift from Amgen, was 
diluted in phosphate-buffered saline (PBS) with 0.1% low endotoxin bovine serum 
albumin (Sigma) and administered by twice daily subcutaneous injection at a dose of 250 
µg/kg/day for the length of time indicated.   
Immunohistochemistry and histomorphometry.   Long bones from pOBCol2.3-GFP 
and wild type mice were processed as previously described (10).  Briefly, femurs and 
tibiae were harvested, fixed overnight in 10% neutral formalin, decalcified by incubating 
in 14% EDTA at 4°C for 7-10 days, and then embedded in paraffin.  Paraffin-embedded 
sections were deparaffinized, rehydrated, and antigen retrieval was performed by soaking 
sections in DeCal Retrieval Solution (Biogenex) per manufacturers’ instructions.  GFP 
expression was assessed using a rabbit anti-GFP polyclonal antibody (Chemicon 
International) and positive cells were visualized using Vector Elite ABC kit and DAB 
substrate (Vector Labs) with Nuclear Fast Red counterstain (Sigma).  Slides were 
analyzed in a blinded fashion to determine the number of osteoblasts per millimeter bone 
perimeter, osteoblast surface percent, bone lining cell surface percent, and osteocyte 
number per trabecular area.  Bone lining cells and osteoblasts were differentiated based 
on morphology.  Analysis was confined to the trabecular metaphysial region distal to the 
growth plate.  Osteoclasts were identified by staining sections for tartrate-resistant acid 
phosphatase (TRAP). Osteoclast number and osteoclast surface were calculated based on 
the presence of TRAP positive cells on trabecular surfaces.   
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Osteoid surface was determined by analyzing undecalcified, methyl methacrylate-
embedded sections stained using the Masson trichrome technique. To determine 
mineralization rate, mice were injected twice with 0.5mg calcein (Sigma) before and after 
7 day G-CSF treatment.  48 hours after the second injection, calvaria were harvested, 
fixed in 70% ethanol, and embedded in methyl methacrylate.  Mineral apposition rate and 
mineralizing surface were analyzed by fluorescent microscopy, as previously described 
(12).  Images were acquired with Nikon microphot SA microscope using Nikon plan 10x 
and 20x objectives (Nikon Instruments) and a digital camera from Colorview Soft 
Imaging System. All parameters were analyzed using OsteoMeasure Histomorphometry 
System (OsteoMetrics).   
Osteocalcin RNA in situ.   Osteocalcin sense and antisense 33P-labeled probes for 
RNA in situ were generated using a SP6/T7 Transcription Kit (Roche) using a plasmid 
generously provided by David Ornitz (Washington University).  RNA in situ 
hybridization was performed as previously described.(13)   
Real-time quantitative RT-PCR.  Femurs were flushed with 1 ml of TRIzol reagent 
(Invitrogen) and RNA was isolated according to the manufacturer's instructions.  Real-
time reverse transcriptase polymerase chain reaction (RT-PCR) was performed as 
previously described (10) using the following primers with FAM/TAMRA probes where 
indicated or using SYBR green (Molecular probes).  
Bglap2 (osteocalcin):  5’-TCTCTCTGCTCACTCTGCTGGCC-3’ (fwd primer); 5’-
TTTGTCAGACTCAGGGCCGC-3’ (rev primer);  5’-
TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3’ (FAM/TAMRA probe).  
Tnfrsf11b (osteoprotegerin): 5’-TACCTGGAGATCGAATTCTGCTT-3’ (fwd primer); 
5’-CCATCTGCACATTTTTTGCAAA-3’ (rev primer); 5’-
ACCGGAGCTGTCCCCCGGG-3’(FAM/TAMRA probe).  Spp1 (bone sialoprotein):  
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5’-ACGGCGATAGTTCCGAAGAGGAGGG-3’(fwd primer);  
5’-GAGTGTGGAAAGTGTGGAGTTCTCTGCC-3’(rev primer).  Akp2 (Alkaline 
Phosphatase): 5’-TCCATCCTGCGCTGGGCCAAGG-3’(fwd primer);  
5’-AGTCCCGATCGGCCGAGTGTGCG-3’(rev primer).  Runx2:  
5’-GCACTGGCGGTGCAACAAGACCC-3’(fwd primer);  
5’-CGGAGTAGTTCTCATCATTCCCGGCC-3’(rev primer).  Tnfsf11 (RANKL):  
5’-GCAACACATTGTGGGGCCACAGC-3’(fwd primer); 5’-
TGGCTGGGCCTCAGGCTTGC-3’(rev primer).  Actb (β Actin): 5’-
ACCAACTGGGACGATATGGAGAAGA-3’(fwd primer); 5’-
TACGACCAGAGGCATACAGGGACAA-3’(rev primer);   
5’-AGCCATGTACGTAGCCATCCAGGCTG-3’(FAM/TAMRA probe). 
 
Isolation of osteoblast lineage cells by flow cytometry.  Bone marrow cells were 
recovered from the femurs of pOBCol2.3-GFP mice by flushing with PBS. The femurs 
were then infused with PBS containing 50 mg/mL type II collagenase (Worthington 
Biochemical) and incubated at 37°C for 15 minutes. The collagenase-treated femurs were 
flushed again with PBS, cells pooled, and the process repeated for a total 6 digests.  Pilot 
experiments demonstrated that virtually all recoverable GFP positive cells were found in 
these 6 digests (data not shown). 
   To quantify osteoblast lineage cells, pooled fractions were stained with 
allophycocyanin (APC)-conjugated anti-mouse CD45 and phycoerythrin (PE) conjugated 
anti-mouse Ter119 antibodies (eBiosciences).  CD45-, Ter119-, GFP+ cells were 
enumerated on a FACScan flow cytometer (Becton Dickenson).  In some experiments, 
CD45-, Ter119-, GFP+ cells were sorted using a MoFlo high-speed cell sorter (Dako). 
BrdU labeling.  pOBCOL2.3-GFP mice were treated with 2mg BrdU (Sigma) daily for 
14 days before G-CSF treatment.  In a separate study, mice were given 2 mg of BrdU 
twice daily for 5 days after G-CSF treatment.  Cell fractions containing osteoblasts were 
isolated as described and stained with PE-conjugated anti-Ter119 and biotinylated anti-
 102 
CD45 coupled with Alexa 750-conjuaged streptavidin (Invitrogen).  BrdU positivity was 
assessed using the BD Pharmingen BrdU Flow Kit (Becton Dickenson) and an Alexa 
647-conjugated anti-BrdU antibody (Invitrogen). 
Activated Caspase 3 analysis. Bone marrow cells harvested from pOBCOL2.3-GFP 
mice were stained with APC-conjugated anti-mouse Ter119 and biotinylated anti-mouse 
CD45 (eBiosciences) coupled with Alexa 750-conjuaged streptavidin (Invitrogen).  Cells 
were then fixed and permeabilized with BD Cytofix/Cytoperm kit and stained with rabbit 
monoclonal PE-conjugated anti-activated Caspase 3 antibody, per manufacturer’s 
protocol (BD Biosciences Pharmingen). 
CFU-F and CFU-Alp culture.  Bone marrow was isolated from mice treated 5 days with 
G-CSF and untreated controls.  3.6 million nucleated cells were plated per well in 6 well 
plates.  Cells were grown for four days in αMEM (Gibco) supplemented with 10% fetal 
bovine syrum and Pen/Strep.  After four days, media was switched to differentiation 
media containing 50 mg/l ascorbic acid and 2.16mg/l Beta-glycerophosphate (Sigma), 
and media was changed every 3-4 days thereafter.  After 14 days culture, cells were 
assayed for alkaline phosphatase positivity using a kit (Sigma), and colonies containing 
more than 20 cells were scored.  
Bone marrow transplantation.  Wild-type (Ly5.1) and G-CSFR-/- (Ly5.2) bone marrow 
cells were harvested from strain- and sex-matched mice.  Cells were stained with PE-
conjugated mouse anti-CD45.1 or anti-CD45.2, APC-conjugated mouse anti-c-Kit, and 
FITC-conjugated lineage markers anti-CD3, anti-GR1, anti-B220, and anti-Ter119 
antibodies.  CD45-positive, c-Kit positive, lineage negative hematopoietic progenitors 
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were purified by high speed cell sorting, and 30,000-50,000 cells were injected into the 
tail vein of each lethally irradiated wild type (Ly5.1) or G-CSFR-/- (Ly5.2) recipient as 
previously described.(14)  Two independent groups of mice received transplants; mice 
were analyzed separately, and the results pooled.  
Statistical analysis.  Data are presented as mean ± SEM. Statistical significance was 
assessed using 2-sided Student t test or two-way ANOVA (BrdU analysis).  
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4.4 RESULTS 
4.4.1  G-CSF treatment results in a loss of osteoblasts but not osteocytes or bone 
lining cells in the bone marrow.  We and others previously showed that treatment with 
G-CSF leads to a loss of cuboidal osteoblasts from the bone marrow in mice.(9,10)  To 
further characterize this process, we first determined the kinetics of osteoblast loss during 
G-CSF treatment.  As shown in Figure 1A, loss of mature osteoblasts, as defined by 
histomorphological criteria, was delayed, with a significant fall only seen after 5 days of 
G-CSF.  This effect was reversible, as osteoblast number recovered within 5 days after 
stopping G-CSF.  
These data were confirmed using transgenic mice expressing GFP driven by a 2.3 
kb fragment of the rat type 1 collagen promoter (pOBCol2.3-GFP mice).  Consistent with 
a previous report (11), we observed GFP expression in these mice in mature, cuboidal 
osteoblasts, morphologically flat bone lining cells, and osteocytes (Figure 1B).  G-CSF 
treatment resulted in a striking loss of GFP+ osteoblasts in trabecular and cortical bone.  
In contrast, G-CSF had no significant effect on the number of GFP+ bone lining cells or 
osteocytes (Figures 1B and 1C). 
We next developed a method to analyze and sort GFP+ osteoblast-lineage cells by 
flow cytometry.  Briefly, hematopoietic and stromal cells were recovered from long 
bones by serial collagenase digestion.  Immunohistochemistry performed on long bones 
after harvesting revealed efficient recovery of GFP+ cells from both control and G-CSF 
treated mice (data not shown).   Osteoblast lineage cells were defined as CD45- Ter119- 
GFP+ cells; CD45+ and Ter119+ cells were excluded to improve specificity. Consistent 
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with the histomorphometry data, this flow cytometry-based assay showed that the number 
of osteoblast lineage cells decreased following G-CSF administration (Figure 1D, 1E).  
 
4.4.2  G-CSF treatment selectively suppresses endosteal and trabecular but not 
periosteal osteoblasts.  To directly assess the effect of G-CSF treatment on bone 
formation, two functional assays of osteoblast activity were measured.  Consistent with 
the loss of mature osteoblasts, a significant decrease in osteoid synthesis was observed in 
tibias of mice treated with G-CSF (Figure 2A).  Similarly, both mineral apposition rate 
and total surface mineralization were decreased on the endosteal surfaces of calvaria 
harvested from G-CSF treated mice (Figure 2B).  However, G-CSF had no significant 
effect on either parameter on the periosteal surfaces of calvaria.  To test whether G-CSF 
treatment preferentially targets endosteal and trabecular osteoblasts in mouse long bones 
as well, we performed RNA in situ hybridization for osteocalcin mRNA.  In untreated 
mice, osteocalcin mRNA was readily detected on endosteal, trabecular, and periosteal 
surfaces (Figure 2C, left).  As expected, G-CSF treatment resulted in a significant 
reduction in osteocalcin mRNA expression in endosteal and trabecular osteoblasts.  In 
contrast, no significant decrease in osteocalcin expression in periosteal osteoblasts after 
G-CSF treatment was observed (Figure 2C, center). Collectively, these data suggest that 
G-CSF selectively suppresses endosteal and trabecular osteoblasts.    
 
4.4.3  G-CSF treatment suppresses osteoblast function through a hematopoietic cell 
intermediate.  The selective targeting of endosteal and trabecular osteoblasts by G-CSF 
suggested the hypothesis that its effects on osteoblasts are mediated by a hematopoietic 
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cell intermediary. To test this hypothesis, bone marrow chimeras were generated by 
transplanting G-CSFR deficient bone marrow cells into wild type mice.  Likewise, 
chimeras were generated in which wild type bone marrow was transplanted in G-CSFR 
deficient recipients.  Since there is evidence suggesting that mesenchymal (stromal) cells 
can be transplanted to recipient mice(15), we sorted hematopoietic progenitor cells 
(CD45+ Kit+ lineage-) to high purity prior to transplantation.  Greater than 95% 
hematopoietic reconstitution with donor cells was confirmed in all chimeras 6-8 weeks 
after transplantation (data not shown).  Chimeric mice were then treated 5 days with G-
CSF and the level of bone marrow osteocalcin mRNA was measured to gauge the effect 
of G-CSF on the osteoblast compartment.   In chimeric mice reconstituted with G-CSFR 
deficient hematopoietic cells, G-CSF treatment had no effect on osteocalcin expression 
(Figure 3A).  In contrast, G-CSF treatment induced a greater than 30 fold decrease in 
osteocalcin mRNA in G-CSFR deficient mice reconstituted with wild type hematopoietic 
cells (Figure 3B).  These data show that G-CSF does not act directly on osteoblasts or 
other stromal cells.  Instead, G-CSF suppresses osteoblasts through activation of a 
(presumably G-CSFR-positive) hematopoietic cell intermediate.   
 
4.4.4  G-CSF treatment increases osteoblast turnover by inducing apoptosis.  The 
loss of mature osteoblasts during G-CSF administration could occur through three 
general mechanisms: increased osteoblast turnover, decreased osteoblast production, or 
induction of osteoblast quiescence (with attendant loss of GFP expression from the type I 
collagen promoter).  To begin to distinguish between these possibilities, we designed an 
experiment to measure the turnover rate of labeled osteoblast lineage cells in the bone 
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marrow.  pOBCol2.3-GFP mice were treated with BrdU for 14 days prior to treatment 
with G-CSF.  This treatment resulted in 32% of osteoblasts lineage (GFP+) cells being 
labeled with BrdU (Figure 4A).  Mice were then treated with G-CSF, and the percentage 
of BrdU-labeled osteoblast-lineage cells in the bone marrow was determined as a 
function of time (Figure 4A).  In control mice, a gradual loss of BrdU+ GFP+ cells was 
observed, with a calculated half-life of 7.7 days.  In mice treated with G-CSF, a more 
rapid turnover of BrdU+ GFP+ cells was observed, with a half-life of 3.7 days.  Of note, 
after stopping G-CSF, the turnover rate of BrdU+ GFP+ cells was similar in both groups 
of mice.   
 The increased turnover of osteoblasts in the bone marrow following G-CSF 
administration suggested that G-CSF may induce osteoblast apoptosis.  Indeed, regulation 
of osteoblast survival is thought to be an important mechanism regulating osteoblast 
number in the bone marrow (16). To test this hypothesis, we determined whether G-CSF 
treatment induced apoptosis of osteoblasts.  Based on the kinetics of osteoblast loss, we 
focused our analyses on day 3 of G-CSF treatment.  GFP+ osteoblast-lineage cells were 
isolated from mice treated 3 days with G-CSF and the percentage of GFP+ cells 
expressing activated caspase 3 was determined by flow cytometry (Figure 4B).  In control 
mice, 4.3±1.1% of GFP+ cells were apoptotic, as measured by activated caspase 3 
expression.  Of note, this number is within the range of reported values for osteoblast 
apoptosis in untreated mice (17-21).  In G-CSF treated mice, the percentage of apoptotic 
cells was significantly increased (9.2 ± 0.6%, p = 0.01).  These data suggest that G-CSF 
treatment suppresses mature osteoblasts, in least in part, by inducing apoptosis.   
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4.4.5  G-CSF administration is associated with the inhibition of osteoblast 
differentiation.  We next asked whether osteoblast differentiation also was impaired 
following G-CSF administration.  We first measured the effect of G-CSF on the 
expression of a panel of genes expressed at different stages of osteoblast differentiation 
(Figure 5A).  G-CSF treatment resulted in a significant decrease in all of the osteoblast 
genes analyzed.  However, the greatest decrease in expression was observed with genes 
expressed late during osteoblast maturation.  Whereas a 19 fold decrease in the late 
osteoblast gene Bglap2 (osteocalcin, OC) was observed, only a 1.8-fold reduction in the 
pan-osteoblast lineage transcription factor Runx2 was noted.   
The relative preservation of early osteoblast gene expression prompted us to 
examine the effect of G-CSF on osteoblast progenitor cells in the bone marrow.  
Specifically, the number of colony forming unit-fibroblast (CFU-F) and progenitor cells 
capable of forming alkaline phosphatase positive colonies (CFU-ALP) was measured.   
G-CSF treatment resulted in a 4.4-fold increase in CFU-F and a 12.6-fold increase in 
CFU-ALP over untreated controls (Figure 5B).   To determine whether this increase in 
osteoprogenitors resulted in a later increase in mature osteoblasts, we extended the period 
of G-CSF administration to 22 days and measured osteocalcin mRNA expression in the 
bone marrow (Figure 5C).  The decrease in osteocalcin mRNA expression was maximal 
by 5 days of G-CSF treatment and remained suppressed throughout the 22 day treatment 
period.  Decreased osteoblast number was confirmed by histology (data not shown).  The 
prolonged loss of osteocalcin-producing osteoblasts, despite the increase in 
osteoprogenitors, suggests that G-CSF administration leads to a defect in osteoblast 
maturation in mice.    
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As noted previously, a prior study suggested that G-CSF treatment might induce 
osteoblast quiescence.  This model predicts that the recovery of mature osteoblasts upon 
discontinuation of G-CSF results from the reactivation of quiescent osteoblasts, rather 
than the production of new osteoblasts.  To test this prediction, we measured BrdU 
uptake by osteoblasts during the recovery period after a five day course of G-CSF.  In 
control mice, 11.5± 2.6% of GFP+ osteoblast-lineage cells were labeled with BrdU at the 
end of the recovery phase, reflecting the rate of recruitment of new osteoblasts during this 
five-day period  (Figure 5D).  In contrast, 31.3± 3.6% of GFP+ cells were labeled in mice 
that had received G-CSF, indicating that the rebound in osteoblast number during the 
recovery phase results from recruitment of new osteoblasts rather than recovery of 
quiescent osteoblasts.   
 
4.4.6  G-CSF administration results in a decreased OPG/RANKL ratio and is 
associated with a late increase in osteoclast number.  Previous studies have established 
that chronic treatment with G-CSF leads to increased osteoclast number and activity in 
the bone marrow. (4-6,22)  Though there is evidence that G-CSF can directly activate the 
osteoclast lineage (8), the potent suppressive effect of G-CSF on osteoblasts suggests 
another possibility.  Namely, since osteoblasts contribute to the regulation of 
osteoclastogenesis, the loss of osteoblasts during G-CSF treatment may secondarily 
activate osteoclasts.  Indeed, the kinetics of the loss in osteoblasts and increase in 
osteoclasts is consistent with this possibility.  While the decrease in osteoblast number 
was maximal after 5 days of G-CSF treatment (Figure 1A), no increase in osteoclast 
number at this time point was noted, a result consistent with previous reports (Figures 6A 
 110 
and 6B) (6,8).  In fact, a significant increase in osteoclasts was not noted until after 
fourteen days of G-CSF treatment.  
A major mechanism by which osteoblasts regulate osteoclast number and activity 
is by the regulated production of receptor activator of NF-Kappa-B ligand (RANKL, 
TNFSF11) and osteoprotegerin (OPG, TNFRSF11B), a decoy receptor for RANKL.  
RANKL and OPG are positive and negative regulators of osteoclasts, respectively; thus, 
the relative expression of these genes is a key determinant of osteoclast activation (24).  
In mice treated with G-CSF for 5 days, no change in RANKL mRNA expression in the 
bone marrow was detected (Figure 6C).  In contrast, a 12-fold decrease in OPG mRNA 
was observed after 5 days of G-CSF treatment (Figure 6C).  The ratio of RANKL to OPG 
mRNA increased from 0.19 at baseline to 1.98 after 14 days of G-CSF.   To verify that 
the loss of OPG mRNA resulted from the loss of osteoblasts, pOBCol2.3-GFP transgenic 
mice were treated with G-CSF, GFP+ osteoblast-lineage cells were isolated, and OPG and 
RANKL mRNA was measured.  While RANKL expression was preserved within this 
fraction after G-CSF treatment, OPG mRNA was reduced 10-fold, consistent with the 
loss of GFP+ mature osteoblasts (Figure 6D).   
 
4.5  DISCUSSION 
In this study, we confirm and extend our previous finding that G-CSF treatment 
suppresses osteoblast number and activity.  This effect appears to be specific to mature 
osteoblasts, as other osteoblast-lineage cells, including osteocytes and bone lining cells, 
are unperturbed.  We provide evidence that G-CSF treatment increases apoptosis of 
mature osteoblasts while increasing the numbers of osteoprogenitors in the bone marrow.  
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Transplantation experiments show that G-CSF regulates osteoblasts in an indirect fashion 
through activation of an undetermined hematopoietic cell intermediary. Finally, we show 
that G-CSF treatment significantly alters the relative expression of RANKL and OPG in 
the bone marrow, providing a novel mechanism by which G-CSF treatment results 
osteoclast activation.   
   Apoptosis is thought to be one of the primary regulators of osteoblast homeostasis 
in the bone marrow.  There is evidence that glucocorticoid treatment and estrogen 
withdrawal suppress osteoblast number through the induction of apoptosis (21,25).  
Conversely, inhibition of osteoblast apoptosis during intermittent parathyroid treatment 
may contribute to the bone anabolic effect seen with this treatment (20).  In the present 
study, we show that G-CSF treatment results in an approximately two-fold increase in the 
turnover rate of BrdU-labeled osteoblast lineage cells in the bone marrow.  Moreover, the 
percentage of cleaved caspase 3-positive osteoblasts recovered from G-CSF treated mice 
was increased two-fold compared with control mice.  Together, these data suggest that G-
CSF regulates osteoblast number in the bone marrow, in part by, inducing osteoblast 
apoptosis. 
The following observations suggest that G-CSF also inhibits osteoblast 
differentiation in vivo.  1) G-CSF administration results in a marked increase in 
osteoprogenitors.  2) The increase in osteoprogenitors does not “rescue” the defect in 
mature osteoblasts, even after prolonged (22 days) G-CSF administration. In contrast, the 
increase in osteoprogenitors observed after estrogen withdrawal, which induces a greater 
degree of osteoblast apoptosis, is able to restore osteoblast number to normal.(26,27)   3). 
Expression of genes associated with earlier stages of osteoblast differentiation (e.g., 
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Runx2) is reduced less than genes associated with later stages (e.g., Bglap2).  4).  Finally, 
the rapid recovery of osteoblasts with proliferating (BrdU-labeled) cells following 
cessation of G-CSF, suggests that G-CSF administration leads to the accumulation of an 
expanded pool of osteoblasts precursors in the bone marrow.   Collectively, these data 
suggest G-CSF administration leads to a loss mature osteoblasts in the bone marrow 
through both an increase in osteoblast turnover and inhibition of osteoblast 
differentiation. 
In addition to hematopoietic cells, there is data suggesting that the G-CSFR is 
expressed on wide range of non-hematopoietic tissues including endothelial cells, 
neurons, and possibly cardiomyocytes (28,29).   Previous studies have shown that the G-
CSFR is not expressed on osteoblast cells lines or cultured primary murine calvarial 
osteoblasts (9,10).  Whether the G-CSFR is expressed on osteoblasts in vivo has not been 
determined, therefore the possibility that G-CSF’s effects on osteoblasts are direct cannot 
be excluded.  In this study, we provide definitive evidence through the use of G-CSFR 
deficient bone marrow chimeras that G-CSF acts indirectly to suppress osteoblasts.  
Indeed, these data strongly suggest that this phenotype is dependent upon a transplantable 
hematopoietic cell intermediate.  Consistent with this conclusion, G-CSF treatment 
preferentially targets endosteal and trabecular osteoblasts, with little effect on periosteal 
osteoblasts. 
The hematopoietic cell population(s) that mediate the suppressive effect of G-CSF 
on osteoblasts are not known.  The G-CSFR is expressed at high levels on neutrophils, 
monocytes, osteoclasts, and hematopoietic progenitors.  There also are reports of G-
CSFR expression on natural killer cells and a subset of B lymphocytes.  However, the 
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suppressive effect of G-CSF treatment on osteoblasts is preserved in RAG1 deficient 
mice, suggesting that lymphocytes are not required for this effect (9).  Studies are 
underway to define the role of neutrophils, monocytes, and osteoclasts in this pathway.    
The pathway leading from hematopoietic cell activation by G-CSF to osteoblast 
apoptosis also remains poorly understood. In a series of elegant studies, Katayama et al 
recently provided evidence that G-CSF-induced osteoblast suppression is mediated by the 
sympathetic nervous system (9).  Our studies of G-CSFR deficient bone marrow chimeras 
strongly suggest that G-CSF does not act directly on neurons to suppress osteoblasts.  
Rather, our data raise the possibility that G-CSF induced activation of hematopoietic cells 
indirectly leads to activation of the sympathetic nervous system and ultimately osteoblast 
apoptosis. 
A consistent feature of G-CSF-induced osteopenia in both humans and mice is 
osteoclast activation.  Previous studies have demonstrated that G-CSF can act directly on 
osteoclast precursors stimulating their differentiation in vitro into mature osteoclasts (8).  
In the present study, we provide evidence for a novel mechanism by which G-CSF 
treatment leads to osteoclast activation.  G-CSF treatment leads to a marked decrease in 
OPG expression in the bone marrow, while levels of RANKL expression remain 
relatively constant. This altered ratio of OPG to RANKL expression is predicted to 
increase RANK signaling in osteoclasts precursors, thereby stimulating osteoclast 
production and activation.  In addition to osteoblasts, RANKL and OPG are also 
expressed by other stromal cells and certain lymphocyte subsets.(24)  However, our data 
suggest that G-CSF specifically targets the osteoblast lineage, as OPG expression was 
markedly decreased after G-CSF administration in sorted GFP+ cells from pOBCol2.3-
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GFP transgenic mice.  Consistent with this conclusion, G-CSF dependent 
osteoclastogenesis was not observed until at least five days after the beginning of G-CSF 
treatment, at which time the G-CSF-induced loss of osteoblasts was complete.  This late 
activation of osteoclasts by G-CSF corroborates reports from other groups (6,8) and 
supports the notion that loss of OPG expression plays an important role in stimulating 
osteoclastogenesis during G-CSF treatment in vivo.   
In summary, G-CSF signaling through hematopoietic cells in the bone marrow 
exerts powerful effects on both osteoblasts and osteoclasts, resulting in imbalance 
between bone formation and resorption.  It is hoped that by continuing to unravel the 
pathways by which G-CSF targets bone cells, greater insight will be gained into how the 
hematopoietic compartment interacts with bone cells.  
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4.7  FIGURE LEGENDS 
 
Figure 4.1  Loss of osteoblast number and function during G-CSF treatment.  (A) Mice were 
treated with G-CSF (250ug/kg/day) for 5 days, and the number of trabecular osteoblasts per mm of 
bone perimeter was determined.  (B) Immunohistochemistry showing GFP positive (brown) 
osteoblasts (arrows), bone lining cells (arrowheads), and osteocytes in untreated or day 5 G-CSF 
treated pOBCol2.3-GFP transgenic mouse femurs.  Insets show enlargement of area enclosed by 
dotted line.  Original magnification 100x, scalebar=200µm.  (C) Quantification of mature 
osteoblasts, bone lining cells, and osteocytes in transgenic mice treated with G-CSF for 5 days or 
untreated (n=4 each group).  (D) Representative scatter plots showing GFP expression (lower 
panels) in the stromal (CD45 negative, Ter119 negative) cell population (upper panels) isolated 
from non-transgenic and pOBCol2.3-GFP mice (left and right respectively).  (E) Shown is the 
number of GFP+ cells recovered from the femurs of transgenic mice after treatment with G-CSF 
(n=2-10 each time point).   Data represent the mean ± SEM.  *P<0.05, **P<0.01. 
 
Figure 4.2  Loss of endosteal and trabecular, but not periosteal osteoblast activity 
during G-CSF treatment.  Osteoid and mineralization were measured in untreated mice or 
mice treated for 7 days with G-CSF (n=2-3 each group).  (A) Percent osteoid surface was 
calculated in Masson trichrome stained tibial sections from untreated and treated wild type 
mice.  (B) Mineral apposition rate and percent mineralizing surface were calculated on 
endosteal and periosteal surfaces from calcein-labeled calvaria.  (C) Osteocalcin RNA in 
situ hybridization of long bones harvested from untreated mice or mice treated for five days 
with G-CSF.  Shown are representative photomicrographs of 3 independent experiments.  
Periosteal surfaces (arrows), endosteal surfaces (arrow heads), bone (B) and bone marrow 
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(BM) are indicated. Original magnification 100x, scalebar=100µm. Data represent the 
mean ± SEM.  *P<0.05. 
 
Figure 4.3  G-CSF receptor knockout bone marrow chimeras.  (A) G-CSFR-/- CD45+ cKit+ 
Lineage- hematopoietic cells (KL) cells were transplanted into wild type recipients (n=4-5 each 
group).  Following hematopoietic reconstitution (6-8 weeks), chimeric mice were treated with G-
CSF (or left untreated), and osteocalcin mRNA expression in the bone marrow was measured by 
real time RT-PCR.  (B) Wild type KL cells were transplanted into irradiated G-CSFR-/- recipients 
(n=6-7, each group) and analyzed in a similar fashion.  Data represent the mean ± SEM.  *P<0.05  
 
Figure 4.4   Osteoblast turnover during G-CSF treatment.  (A) Transgenic pOBCol2.3-GFP 
mice (n=5-6, each group) were administered BrdU for four fourteen days and then either treated 
for 5 days with G-CSF or left untreated.  Mice were analyzed just prior to G-CSF treatment, after 5 
days of G-CSF treatment, or after a 5 day recovery period (arrow heads).   Shown is the percent of 
GFP+ cells in the bone marrow that were labeled with BrdU.  (B)  Representative scatter plots 
showing activated caspase 3 staining in the GFP+ cell population from untreated (left) or G-CSF 
treated pOBCol2.3-GFP mice (right).  (C) Shown is the percentage of GFP+ cells that express 
activated caspase 3 from untreated and day 3 G-CSF-treated mice (n=4 each group).  Data 
represent the mean ± SEM.  *P<0.05, **P<0.01. 
 
Figure 4.5  Analysis of early osteoblast lineage cells during G-CSF treatment.  (A) 
Real time RT-PCR for the indicated genes was performed on total bone marrow RNA 
isolated after 5 days of G-CSF treatment.  RNA expression relative to β-actin mRNA was 
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calculated and compared with untreated bone marrow (assigned a value of 1; n=5-12). (B) 
Shown is the number of alkaline phosphatase negative (CFU-F, left) and positive (CFU-
Alp, right) colonies generated from the bone marrow of untreated or G-CSF treated mice 
(n=5-6 each group).  (C)  Mice (n=2-4 each time point) were treated with G-CSF for the 
indicated period up to 22 days.  Mice were sacrificed at time points and analyzed for 
osteocalcin mRNA by real time RT-PCR.  (D)  Mice (n=6, each group) were treated 5 days 
with G-CSF or left untreated and then administered BrdU for five days during the recovery 
period.  Shown is the percent of GFP+ cells in the bone marrow that were labeled with 
BrdU.  Data represent the mean ± SEM.  *P<0.05, **P<0.001. 
 
Figure 4.6  Osteoclastogenesis during G-CSF treatment.  (A and B) Wild type mice 
(n=2-6 each group) were treated with G-CSF for the indicated time or left untreated.  
Osteoclast number (A) and surface (B) were estimated by enumerating TRAP positive cells 
in paraffin embedded sections of mouse long bones.  (C)  RANKL and OPG mRNA 
expression in the bone marrow of untreated or 5-day G-CSF treated mice (n=5-8 each 
group) was measured by real time RT-PCR.  (D) GFP+ cells were sorted from G-CSF-
treated pOBCol2.3-GFP mice.  RANKL and OPG mRNA was measured within this 
fraction.  Data represent the mean ± SEM.  *P<0.05, **P<.01 
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The major goal of this thesis was to clarify the role of CXCL12/CXCR4 signaling in 
cytokine-induced mobilization and refine our understanding of how CXCL12 expression 
decreases in the bone marrow during G-CSF treatment.  Unexpectedly, we uncovered a 
role for osteoblasts in regulating HSPC trafficking during cytokine treatment and have 
demonstrated a role for the hematopoietic compartment in regulating bone homeostasis 
by mediating osteoblast apoptosis and differentiation.  While we have observed this 
phenomenon only in the rather specialized and non-physiologic setting of cytokine-
induced mobilization, it is possible that further study will reveal a critical and reciprocal 
dependence between the hematopoietic and osteoblast compartments.  Finally, recent 
reports that osteoblasts play a key role in maintaining the hematopoietic stem cell niche 
raise the possibility that cytokine treatment leads to mobilization in part by disrupting the 
stem cell niche.   
 
5.1  Osteoblasts are a major source of bone marrow CXCL12 and decrease in 
number with G-CSF treatment.  In Chapter 2 of the thesis, we investigate the decrease 
in bone marrow expression of CXCL12 observed during G-CSF treatment by comparing 
CXCL12 expression in different bone marrow populations.  To this end, a novel method 
of isolating stromal cells, including bone-adherent osteoblasts, by subjecting mouse 
bones to serial collagenase digests was developed.  Isolated cells were fractionated into 
hematopoietic, osteoblast, endothelial, and primitive mesenchymal progenitor fractions 
by high speed flow cytometry-based cell sorting.  It was demonstrated that the osteoblast 
fraction was highly enriched for CXCL12 expression, suggesting that osteoblasts may 
play an important role in HSPC mobilization.  Therefore, osteoblast number was 
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compared in mice treated with G-CSF or left untreated, and a roughly 50% reduction in 
the number of histologically identifiable endosteal and trabecular osteoblasts was 
observed.  This finding corroborates previous data by Takamatsu et al who found that 
serum osteocalcin decreases in humans treated with G-CSF.1 The loss of osteoblasts 
combined with the observation that osteoblasts represent a major source of bone marrow 
CXCL12 raise the possibility that the decrease in osteoblasts may play an important role 
in mobilization.   
 
5.2  Loss of osteoblast-derived CXCL12 plays a critical role in cytokine-induced 
mobilization.  Chapter 3 furthers these studies on the role of osteoblasts in mobilization 
by providing three observations.  First, loss of osteoblasts and disruption of 
CXCL12/CXCR4 signaling is a common finding in mobilization induced by G-CSF, 
Flt3L, and SCF.  Second, the decrease in bone marrow CXCL12 in cytokine-induced 
mobilization is attributable specifically to the loss of osteoblast-produced CXCL12.  
Third, disruption of CXCL12/CXCR4 signaling is the principle pathway by which G-
CSF induces mobilization.  This latter finding was highlighted in experiments that 
showing that an antagonist of VLA-4 sigaling—but not G-CSF—increased the number of 
circulating HSPC in the genetic absence of CXCR4 in hematopoietic cells.   These data 
strengthen the association between decreased osteoblast number and HSPC mobilization.   
 
5.3  G-CSF treatment increases osteoblast apoptosis and blocks differentiation 
through a hematopoietic intermediary.  Chapter 4 of the thesis investigates in more 
detail the effect that G-CSF has on osteoblast number and function.  The kinetics of 
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osteoblast loss were found to mirror mobilization, with no osteoblast loss detected until 
day 4 of treatment.  Both osteoid formation and bone mineralization was reduced by G-
CSF treatment, consistent with the loss of osteoblasts, and mRNA expression of 
osteoblast markers Runx2, bone sialoprotein, alkaline phosphatase, and osteocalcin were 
sharply decreased.  The loss of osteoblasts does not result from failure of osteoprogenitor 
commitment, as the number of alkaline phosphatase positive CFU-F was strikingly 
increased with G-CSF treatment.  Instead, by making use of transgenic mice expressing 
GFP in osteoblast lineage cells (pOBCol2.3-GFP mice) we determined that the half life 
of labeled osteoblasts decreased by half during G-CSF treatment.  This decrease may be 
due to accelerated apoptosis, as there was a roughly 2-fold increase in the percent of 
activated caspase 3 positive osteoblasts in G-CSF treated mice.  Interestingly, despite the 
increase in osteoprogenitor number, osteoblast number and osteocalcin expression never 
recover with prolonged G-CSF treatment (up to 22 days) suggesting that G-CSF blocks 
osteoblast development.  Finally, we generated bone marrow chimeras by transplanting 
G-CSF receptor deficient hematopoietic cells into wild type mice and administered G-
CSF.  These mice failed to mobilize and had no decrease in osteocalcin expression, 
showing that the effect of G-CSF on osteoblasts is indirect and requires signaling through 
the hematopoietic compartment.  The nature of these signals and the identification of the 
hematopoietic cell type(s) involved will be a major goal of our lab in the future. 
 
5.4  Bone marrow monocytes may play a key role in supporting osteoblasts.  As a 
first step toward understanding the molecular pathways by which G-CSF regulates 
osteoblasts, we hope to identify the hematopoietic cell type or types that are required for 
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G-CSF-induced suppression of osteoblasts.  Hematopoietic cell types likely to regulate 
osteoblasts include lymphocytes and monocyte/osteoclast lineage cells.  However, mice 
deficient in lymphocytes due to the Rag2 gene mobilize normally, making it unlikely that 
lymphocytes mediate this effect. (2 and D.C.L. unpublished data)  Therefore we 
hypothesize that osteoblast development and apoptosis are mediated by monocyte lineage 
cells in the bone marrow during G-CSF treatment.  The first approach we are using to 
address this hypothesis is to generate transgenic mice that express the G-CSF receptor 
under control of the human CD68 promoter.3,4  This promoter is expected to direct G-
CSF receptor expression in monocyte and macrophage lineages only, and when crossed 
with our G-CSF receptor deficient mice would generate offspring where the G-CSF 
receptor expression is restricted to monocytes and macrophages.   These mice will then 
be tested for response to G-CSF.   
     The second approach to testing the hypothesis that bone marrow monocytes mediate 
G-CSF effects on osteoblasts has been to administer G-CSF to transgenic mice whose 
monocyte lineage cells have been ablated by a monocyte-expressed suicide gene.  So-
called Mafia (“Macrophage Fas-induced Apoptosis”) mice lose monocyte lineage cells 
when treated 5 days with a synthetic suicide receptor ligand, referred to as the 
“dimerizer.” 5,6  Mafia mice treated five days with dimerizer mobilize HSPC to peripheral 
blood, an effect accompanied by a striking loss of osteocalcin expression and identifiable 
osteoblasts (Figure 5.1B-C) with no discernable effect on osteoclasts or osteoprogenitors 
(not shown).  These results suggested two possibilities.  First, the loss of monocytes may 
result in the loss of a factor that osteoblasts need for survival.  Alternately, the loss of 
monocytes may result in non-specific toxicity in osteoblasts.  To help distinguish 
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between these two possibilities, mixed chimeras were generated by transplanting wild 
type and Mafia bone marrow mixed 1:1 into lethally irradiated hosts.  If loss of 
monocytes removes a factor that osteoblasts need for survival, it may be supposed that in 
the absence of one half the normal complement of monocytes, most osteoblasts will 
survive.  On the other hand, if loss of monocytes causes release of a toxic factor, loss of 
even one half of total monocytes would cause measurable toxicity.  In 1:1 mixed wild 
type to Mafia chimeras, dimerizer treatment resulted in no significant loss in osteocalcin 
expression, compared to 760-fold reduction in dimerizer-treated Mafia mice (Figure 
5.1D).  These results suggest that bone marrow monocytes may play a role in steady state 
maintenance of osteoblasts.  Further work will be required both to confirm these findings 
and to identify a putative monocyte-derived factor that supports osteoblasts. 
 
5.5  Loss of osteoblasts during G-CSF treatment severely compromises 
hematopoietic stem cell function.  As osteoblasts play a critical role in maintaining the 
hematopoietic stem cell (HSC) pool, we have performed some preliminary experiments 
assessing the function of HSC after G-CSF treatment.  Repopulating function of HSC 
from G-CSF treated mice is markedly reduced compared to untreated HSC in a 
competitive repopulation assay, which is the gold standard measure of stem cell 
function.7  This effect is seen in both primary and secondary transplants (Figure 2A-B) 
and is present even when bone marrow from treated animals is injected intrafemorally, 
suggesting that it does not result from an artifactual failure to home to the bone marrow 
of irradiated recipients (Figure 2C).  Further work on characterizing the precise molecular 
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defect in HSC from G-CSF treated mice is being continued by Priya Gopalan, an 
Oncology Fellow in the lab.   
 
5.6  Conclusion.  The studies described in this thesis shed light on molecular 
underpinnings of HSPC both by demonstrating the interdependence of previously 
described mechanisms and by revealing a novel mechanism involved in mobilization, 
cytokine-induced loss of osteoblasts.  When this work was begun, the prevailing model 
for HSPC mobilization centered on the role of proteases, upregulated by G-CSF 
treatment, which work through pathways organized in parallel (Figure 5.3A).  Proteolytic 
cleavage of integrins, hyaluronic acid, c-Kit, and CXCL12 all contribute to mobilization 
in this model.  The work presented here, however, suggests a somewhat different model 
(Figure 5.3B).  The finding that G-CSF treatment leads to loss of bone marrow 
osteoblasts and CXCL12 mRNA (Chapter 1) raises the possibility that protease activation 
is not necessary for clearance of CXCL12.  That G-CSF does not increase mobilization in 
the absence of CXCR4 signaling (Chapter 2) suggests that this one pathway is sufficient 
to mediate HSPC mobilization during G-CSF treatment.  In this revised model, loss of 
osteoblasts—an indirect effect of G-CSF treatment mediated through the hematopoietic 
system—is upstream of CXCL12/CXCR4 disruption, and future research will focus on 
what lies upstream and downstream of this signaling axis. 
     It bears noting that the implications of these findings extend beyond the field of HSPC 
mobilization.  First, the loss of osteoblasts results in a significant, although temporary, 
loss in HSC repopulation ability.  Better understanding G-CSF-induced osteoblast 
depletion and its downstream effects on HSC may lead to important discoveries about 
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HSC biology and factors that sustain HSC in their bone marrow niche.  Second, 
identifying pathways by which the hematopoietic compartment regulates osteoblast 
apoptosis and differentiation may improve our understanding of bone homeostasis and 
how the hematopoietic compartment and the bone compartment regulate each other’s 
function.  Thus G-CSF-induced mobilization may prove to be a useful platform for 
improving our understanding of wider biological processes.   
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5.8  FIGURE LEGENDS 
 
Figure 5.1.  Monocytes may play a key role in supporting osteoblast survival in vivo.  
Mafia transgenic mice (n=5 each group) were treated with dimerizer or vehicle to induce 
monocyte death.  (A) HSPC mobilization as measured by number peripheral blood CFU-
C.  (B) Total bone marrow osteocalcin mRNA as measured by Q-RT-PCR.  (C) 
Representative photomicrograph showing TRAP stained paraffin sections from long 
bones of vehicle treated (left) or dimerizer treated (right) mice.  Osteoblasts are difficult 
to find in the right panel, although red-staining osteoclasts are abundant. (D) Wile type 
and Mafia bone marrow was mixed at a 1:1 ratio and transplanted into irradiated 
recipients.  Resulting mixed chimeras were treated 5 days with dimerizer or vehicle, 
RNA was isolated from long bones and osteocalcin mRNA was measured.  The 
difference was not statistically significant.  Data represent mean ± SEM.  *p<.05    
 
Figure 5.2.  G-CSF treatment causes loss of hematopoietic stem cell function.  Ly5.1 
mice were treated 7d with G-CSF or left untreated then injected with an equal number of 
unmanipulated Ly5.2 cells into lethally irradiated Ly5.1/5.2 hosts (n=5 each group).  
Shown is peripheral blood chimerism of Ly5.1 test cells eight months up to eight months 
post transplant in mice that received (A) intravenous or (B) intrafemoral transplants. (C) 
After 8 months, primary recipients were harvested and transplanted into irradiated 
secondary recipients who were subsequently analyzed 6 weeks later for peripheral blood 
chimerism in B220, Gr-1, and CD3 lineages.   Data represent mean ± SEM.  *p<.01    
 
Figure 5.3.  Two competing models for G-CSF-induced HSPC mobilization.  (A) 
Previous reports suggested a model where a variety of adhesive or chemotactic 
interactions worked in parallel to mediate HSC retention in the bone marrow (left).  In 
this model, these interactions are attenuated by proteolytic cleavage upon G-CSF 
treatment.  (B) Model of G-CSF-induced mobilization as suggested by experiments 
presented here.  At steady state monocytes produce trophic factor to maintain osteoblast 
compartment.   G-CSF acts on monocytes to downregulate trophic factor, resulting in loss 
of osteoblasts.  Loss of osteoblast CXCL12 expression in this model is sufficient to lead 
to mobilization.  
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